

Antimicrobial Resistance
and Sensitivity of
Phytophthora agathidicida.

by

Kaitlyn Daley

A thesis submitted to the Victoria University of Wellington
in fulfilment of the requirements for the degree of Master of Science.

Victoria University of Wellington

2020

Abstract

Members of the oomycete genus *Phytophthora* are highly infectious plant pathogens. *P. agathidicida* affects the New Zealand native keystone species *Agathis australis* (kauri) and is the cause of kauri dieback. The complex oomycete lifecycle makes *Phytophthora* infections hard to manage. The current management of kauri dieback has been limited and antimicrobial resistance is a concern. Phosphite agrichemical preparations are commonly used in the control of *Phytophthora* diseases, including kauri dieback. However, phosphite is not the only option; the agrichemicals oxathiapiprolin, and the plant-derived natural products polygodial and falcarindiol, have also been shown to have activity against *P. agathidicida*. The overall goal of this thesis was to further explore aspects of sensitivity and resistance of *P. agathidicida* towards these four compounds.

In New Zealand, there are three commercially available phosphite preparations, Agri-Fos 600, Phosgard, and Foschek. All previous studies have used Agri-Fos 600, so the first aim was to determine whether the particular formulation altered anti-oomycete activity. No significant difference was found between the 50% inhibitory concentrations (EC₅₀ values) for the three formulations. Interestingly, however, formulating polygodial and falcarindiol with the surfactants and other non-phosphite ingredients of Foschek led to a significant increase in their inhibitory effects.

The second aim of this thesis was to implement a serial passaging protocol for *P. agathidicida* and attempt to isolate mutants with increased resistance to phosphite, polygodial or falcarindiol. Serial passaging was carried out on amended agar plated with increasing concentrations of each chemical. However, even after 7 passages, over 16-18 weeks of growth, no mutants with increased resistance were isolated. This could be due to the complicated modes of action of the polygodial, falcarindiol and phosphite, which makes it likely that several specific mutations are required to effect resistance.

Oxathiapiprolin is a highly potent, new anti-oomycete agrichemical. It targets the *Phytophthora* oxysterol binding protein (OSBP) related protein (ORP1). Mutations in this protein are known to give oxathiapiprolin resistance in other species of *Phytophthora*; however, the *P. agathidicida* protein (PaORP1) has never been studied. In this work, the gene for PaORP1 was partially sequenced from five *P. agathidicida* isolates. None contained any of the known resistance mutations. A new protocol for expressing PaORP1 in *E. coli* and purifying it using immobilised metal affinity chromatography was also developed. After optimisation, this protocol yielded up to 30 mg of purified protein per litre of *E. coli* culture and is the first successful example of heterologously expressing and purifying any *P. agathidicida* protein. In future, this will allow the biomolecular interaction between PaORP1 and oxathiapiprolin to be studied in more detail.

Overall, the work presented in this thesis assessed commercial formulations of phosphite, established a directed evolution protocol for studying resistance in *P. agathidicida*, and reported the first *in vitro* characterisation of a *P. agathidicida* protein. This research suggests that commercial formulation of plant-derived natural products may be a powerful new approach for combatting kauri dieback and, promisingly, also suggests that the risk of developing resistance to these compounds might be low.

Acknowledgements

First and foremost, I would like to thank my supervisor, Wayne Patrick, words cannot express my gratitude for all the opportunity, support, guidance and patience you provided throughout this thesis. You always encouraged the best out of me, and for that, I am very grateful.

I would like to extend my appreciation to Monica Gerth. The passion you have expressed for the conservation of kauri has inspired the same passion in me. I am very grateful to be part of such an amazing project and would like to express my gratitude for the opportunity to work as part of the team.

A large thank you to for the MME laboratory group for the wonderful working environment. You have all made my post-graduate adventure memorable. Thank you for the support, the laughs, the parties and the lab adventures.

A special thanks to those on the *Phytophthora* team. In particular thank you to Mike, Randy and Monica S., for all the great chats, constant support, and laughs throughout this often weird but wonderful research.

To all my family, thank you for the support to get through the most academically challenging period. Thank you for all the never-ending support and constant belief in me. Thank you for all the reassuring phone calls.

Thank you to all my friends, Jaybee, Aimee, Patrika, and Russyl, who have given me unconditional encouragement throughout this period. Your support has always helped in times of stress. Thank you all for your unconditional friendship when I cancelled on our plans many times.

Thank you to all those who have experienced the postgraduate experience with me. Thank you to Jess, Janine and Sharna for all the support during those tough courses of ours Masters. Thank you, Tessa, for sharing the journey from undergraduate to

postgraduate with me. It has been an adventure in tenacity, determination and personal evolution for all of us.

Lastly, I would like to thank Ben, who gave unconditional love and encouragement throughout this period and support for all the decisions I have made regarding my study. You have endured the lows and celebrated the highs with me, thank you.

Table Of Contents

Chapter 1	<i>Introduction</i>	1
1.1	The Kauri Tree	2
1.1.1	Biological Role	3
1.1.2	Economic Impact.....	3
1.2	Phytophthora Species	3
1.2.1	Life Cycle of <i>Phytophthora</i>	4
1.3	Treatments	7
1.3.1	Phosphite Agrichemicals.....	7
1.3.2	Oxathiapiprolin.....	11
1.3.3	Polygodial.....	12
1.3.4	Falcarindiol.....	14
1.4	Antimicrobial Resistance	15
1.4.1	Phosphite Resistance	15
1.4.2	Oxathiapiprolin Resistance	16
1.5	Aims of this Research:	16
1.5.1	Aim 1	16
1.5.2	Aim 2	16
1.5.3	Aim 3.....	17
1.5.4	Aim 4.....	17
Chapter 2	<i>Materials and Methods</i>	18
2.1	Materials	19
2.1.1	General Materials	19
2.1.2	Phytophthora agathidicida Isolates	19
2.1.3	Bacterial Strains.	19
2.1.4	pET28 Plasmid.....	20
2.1.5	Agrichemicals	23
2.1.6	Antibiotics and Natural products.....	23
2.1.7	PARP Agar	23
2.1.8	V8 Agar	24
2.1.9	Potato Dextrose Agar (PDA).....	24
2.1.10	Carrot Broth.....	25
2.1.11	Terrific Broth	25
2.1.12	Auto Induction Medium.....	25
2.1.13	LB Broth.....	25

2.1.14	PCR Primers.....	25
2.1.15	Protein Purification Buffers.....	26
2.1.16	Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE)	27
2.2	Methods.....	28
2.2.1	Routine Agar Culturing	28
2.2.2	Broth Culturing	28
2.2.3	Amended Media	28
2.2.4	In Vitro Growth Assays	29
2.2.5	Serial Passaging.....	29
2.2.6	DNA Extraction	30
2.2.7	DNA Agarose Gel.....	30
2.2.8	Polymerase Chain Reaction (PCR)	30
2.2.9	DNA Sequencing.....	31
2.2.10	Bioinformatics	31
2.2.11	Freezer Stocks.....	32
2.2.12	Overnight Cultures	32
2.2.13	Electrocompetent Cells.....	32
2.2.14	Transformation.....	32
2.2.15	Enzyme Digest of Plasmid.....	33
2.2.16	SDS-PAGE.....	33
2.2.17	Protein Purification	34
2.2.18	Size Exclusion Chromatography	36
2.2.19	Fluorescence Thermal Shift Assay	37
Chapter 3	<i>Phosphite Formulations.....</i>	<i>39</i>
3.1	Assessment of Agrichemical Formulation.....	40
3.2	Agrichemical Formulations	40
3.3	Adjuvants and Surfactants.....	42
3.3.1	Natural Products and Adjuvants.....	43
3.4	Discussion	44
3.4.1	Quantifying Growth Inhibition	44
3.4.2	Phosphite EC ₅₀ Data	45
3.4.3	Using Adjuvants to Enhance the Bioactivity of Natural Products	46
3.4.4	Treatments for Kauri Dieback.....	46
Chapter 4	<i>Investigating the Potential of Antimicrobial Resistance.....</i>	<i>47</i>
4.1	Results	48
4.1.1	Serial Passaging.....	48

4.1.2	Serial Passaging in the Presence of Polygodial.....	49
4.1.3	Serial Passaging in the Presence of Falcarindiol.....	51
4.1.4	Serial Passaging in the Presence of Phosphite.....	53
4.2	Discussion	54
4.2.1	Resistance Assessment.....	54
4.2.2	Solvent Used to Dissolve Natural Products.....	55
4.2.3	Long Term Implications for Kauri Dieback.....	56
 Chapter 5 Protein Characterisation		57
5.1	Results	58
5.1.1	Bioinformatics	58
5.1.2	Gene Sequencing	59
5.1.3	Gene Synthesis and Protein Modelling	60
5.1.4	Confirmation of Plasmid Insert.	61
5.1.5	Initial Protein Expression and Purification.....	62
5.1.6	Optimisation of Purification	64
5.1.7	Fluorescence Thermal Shift assay.....	66
5.1.8	Size Exclusion Chromatography	67
5.2	Discussion	69
5.2.1	Protocol Development	69
5.2.2	PaORP1 Purity, Stability and Oligomeric State.....	69
5.2.3	Next Steps.....	70
 Chapter 6 Discussion.....		72
6.1	Research Overview	73
6.2	Phosphite Treatment Viability.....	73
6.3	Natural Products and a Basis for Agrichemical Development.....	74
6.4	International Standards for Risk of Resistance.....	75
6.5	Attempted Evolution of Resistance.....	76
6.6	Expression and Purification of <i>P. Agathidicida</i> Proteins.....	77
6.7	Conclusion.....	78
 References.....		79

List Of Figures

FIGURE 1.1 LIFE CYCLE OF <i>PHYTOPHTHORA AGATHIDICIDA</i>	5
FIGURE 1.2 CHEMICAL STRUCTURE OF PHOSPHATE AND PHOSPHITE OXYANION.	9
FIGURE 1.3 1-(4-{4-[5-(2,6-DIFLUOROPHENYL)-4,5-DIHYDRO-3-ISOXAZOLYL]-2-THIAZOLYL}-1-PIPERIDINYL)-2-[5-METHYL-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]ETHENONE (OXATHIPIPROLIN), SOLD COMMERCIALY AS ZORVIC OR SEGOVIS.	11
FIGURE 1.4 THE CHEMICAL STRUCTURE OF THE NATURAL PRODUCT POLYGODIAL.	13
FIGURE 1.5 THE CHEMICAL STRUCTURE OF THE NATURAL PRODUCT FALCARINDIOL.	14
FIGURE 2.1 PET28 PLASMID WITH PAORP1 DNA INSERT.	21
FIGURE 3.1 AGRICHEMICAL INHIBITION GRAPHS.	41
FIGURE 3.2 INHIBITION OF ADJUVANTS, SURFACTANTS AND STABILISING AGENTS.	43
FIGURE 3.3 NATURAL PRODUCTS COMBINED WITH THE LONZA ADJUVANT MIX.	44
FIGURE 4.1 FLOW DIAGRAM FOR EVOLVING <i>P. AGATHIDICIDA</i> FOR RESISTANCE TOWARDS POLYGODIAL, FALCARINDIOL AND PHOSPHITE.	49
FIGURE 4.2. MORPHOLOGY CHANGES IN POLYGODIAL AT ORIGINAL EC ₅₀ , 0.64MG/ML.	50
FIGURE 4.3 GROWTH RESPONSE CURVES FOR <i>P. AGATHIDICIDA</i> 3770, THE EVOLVED ISOLATE, AND THE <i>P. AGATHIDICIDA</i> ISOLATE 3813.	51
FIGURE 4.4. MORPHOLOGY CHANGES SEEN IN FALCARINDIOL.	52
FIGURE 4.5 EVOLUTION OF FALCARINDIOL, <i>P. AGATHIDICIDA</i> ISOLATES VS AN EVOLVED ISOLATE.	53
FIGURE 4.6 EVOLUTION OF PHOSPHITE, <i>P. AGATHIDICIDA</i> ISOLATES VS AN EVOLVED ISOLATE.	54
FIGURE 5.1. <i>PAORP1</i> GENE AND PROTEIN ANNOTATION.	59
FIGURE 5.2. STRUCTURES OF ORDS FOR PAORP1 AND KES1/Osh4.	61
FIGURE 5.3. ENZYME DIGEST OF PAORP1 PET28A PLASMID.	62
FIGURE 5.4. INITIAL EXPRESSION AND PURIFICATION TRIALS OF PAORP1 PROTEINS (WILD TYPE AND MUTANT).	63
FIGURE 5.5. CHANGES IN PROTEIN ABUNDANCE ASSOCIATED WITH THE OPTIMISATION OF THE PROTOCOL.	65
FIGURE 5.6. OPTIMIZED EXPRESSION AND PURIFICATION OF PAORP1 (WILD TYPE AND MUTANT).	66
FIGURE 5.7. SIZE EXCLUSION CHROMATOGRAPHY OF PAORP1 VARIANTS: WILD TYPE (LEFT) AND G771W MUTANT (RIGHT).	68

List Of Abbreviations

DMSO	Dimethyl Sulfoxide
EC ₅₀	50% Inhibition Of Growth
EDTA	Ethylenediaminetetraacetic Acid
FTS	Fluorescence Thermal Shift
IMAC	Immobilised Metal Affinity Chromatograph
IPTG	Isopropyl β -D-1-Thiogalactopyranoside
OD ₆₀₀	Optical Density Reading At A Wavelength Of 600 Nm
ORD	Oxysterol-Binding Domain
ORPs	Oxysterol Binding Protein-Related Proteins
OSBP	Oxysterol Binding Proteins
Osh	Oxysterol Binding Proteins Homologue
SDS-PAGE	Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis
SEC	Size Exclusion Chromatography
TB	Terrific Broth

Chapter 1

Introduction

Once, long ago, the sky father and earth mother had a love so strong, their embrace encased the world in darkness. Within their embrace, they had trapped their six children in the darkness and away from the light. Until one day, the sky father stirred and let a single beam of light in onto their children. The children yearned to free themselves and enter the world of light. Together they discussed separating the sky father and the earth mother.

All but one son agreed, and the other sons began to work on breaking the embrace of the earth mother and sky father. Their parents' love was too strong, and none succeeded, until Tāne Mahuta (god of the forest) lay on his back and with his legs Tāne pushed against his father.

Tāne pushed harder and harder until the bond between his parents began to tear. The light shone into the world. When Tāne fully extended his powerful legs, He forced the sky father into the heavens and flooded the world with light. The son who did not agree, Tawhiri-matea, was angered by the separation of his parents and went to the heavens with his father. Along with his children: Wind, Rain and Storms. From time to time they hurl themselves down in anger at the world ¹.

1.1 The Kauri Tree

The legendary kauri tree, Tāne Mahuta, still separates the earth mother and sky father today. He stands in Waipoua forest, with his shoulders pushed hard against his 'earth mother', and his feet stretched high towards the heavens. Tāne Mahuta is one of the oldest and largest trees in the world at 51 m high and with a girth of 13.8 m. Alongside Tāne Mahuta, Te Matua Ngahere (the father of the forest) is the second-largest kauri tree. He has considerably more girth than Tāne Mahuta, at 16.5 m, but is shorter in height (29.9 m).

These two trees hold significant cultural importance for Māori, and indeed for all New Zealanders. Māori consider kauri to be taonga (a treasure) and a sign of general well-being of the ngahere (forest) and the people. Kauri are widespread in the native forests of northern New Zealand.

1.1.1 Biological Role

Kauri are subtropical conifers ². The biomass produced by kauri change the forest environment and provide an enriched environment for an extensive range of other native flora that thrive under their canopy. Kauri trees provide nitrogen-rich soil from their leaf litter decomposition for the developing forest ³ and a distinctive vegetation that surrounds them ⁴. The forest contains different species of *Podocarpus* (native hardwoods), *Cyperaceae* (Grasses and Sedges), *Alseuosmiaceae* (urn-shaped or funnel-shaped flowering plants), and various myrtle species. These species associate with kauri, where they are usually found under the canopy and within the dripline.

Now, the giant kauri are under threat from an oomycete named *Phytophthora agathidicida*. *P. agathidicida* is a newly described, highly pathogenic microorganism ⁵, ⁶ that is beginning to have a profound impact on the New Zealand native Kauri forests. For example, the proportion of kauri trees showing signs of infection in the Waitākare Ranges area rose from 8% (2008) to 18.95% in 2011 and further to 22.65% by 2016 ⁷.

1.1.2 Economic Impact

Kauri forests are essential for tourism in Northland. It has been estimated that the spread of kauri dieback disease in Northland could reduce the tourism industry by \$50 million per annum as of 2017 ⁸.

1.2 Phytophthora Species

There are more than 500 known species of oomycetes, commonly known as water moulds, white rusts, or downy mildew ⁹. The *Phytophthora* genus are notorious plant pathogens and make up six of the top ten plant pathogens as voted by plant pathologists ¹⁰.

Phytophthora species have a complex lifecycle that superficially resembles that of fungi. However, modern molecular genetics suggest that the oomycetes are related

to brown algae and diatoms ^{11, 12} with *Phytophthora* species lacking the chitin-based cell wall ¹³⁻¹⁵ and ergosterol biosynthesis pathways ¹⁶ of true fungi. Instead, *Phytophthora* cell walls are made up of cellulose, glycoproteins and other polysaccharides ¹⁷.

1.2.1 Life Cycle of *Phytophthora*

Phytophthora species have an elaborate life cycle (Figure 1.1). They can spread through asexual production of motile zoospores, and produce two different types of survival spores; asexually produce chlamydospores and sexually produced oospores. Each stage of the life cycle is a potential target for anti-*Phytophthora* compounds. Unfortunately, while a compound may be effective against one life cycle stage, it may be ineffective against another aspect of the life cycle.

The motile zoospores are produced from the terminal hyphae extensions forming specialised branches called sporangia. Usually, six or more zoospores are held within the sporangia. When the apical point of the sporangia opens, the zoospores are released by turgor pressure into the environment ¹². The release of zoospores usually occurs under cool, humid conditions ⁹.




Figure 1.1 Life cycle of *Phytophthora agathidicida*.

The life cycle of *Phytophthora* begins and ends in the mycelium infection within a tree. When nutrients are low, the mycelium produce a specialised hyphae-call the sporangia. The sporangia contain motile zoospores. These motile spores swim through water logged soil towards a new host and encyst to start a new infection. The established infection forms a network of mycelium throughout the root system of the host.

Zoospores are well characterised. They are mono-nucleated ¹² and lack a cell wall. The outer surface is a phospholipid membrane ¹⁸ with two flagella, posterior and anterior ¹⁸. The posterior flagellum acts to turn the zoospore, and direct is as it swims. The anterior flagellum propels the zoospore backwards ¹⁸. The zoospores are attracted to the roots of the host plants through a process called chemotaxis ¹². The chemo-attractive agents are different for each host species. They include sugars, amino acids, alcohols and vital metabolites produced by the host plant ^{9, 12, 18}. *P. agathidicida* is highly attracted to exudates of kauri root ¹⁹ and currently only known to infect Kauri trees.

Infection occurs once the zoospore reaches the root surface^{9, 12, 18}. The process of spore adhesion and encystment is different from true fungi; no extra stimuli are required other than the root surface¹². Encystment occurs rapidly as the zoospores align themselves along the ventral surface of the root, and the flagella extend towards the root²⁰. Several vacuoles are expelled rapidly from the zoospore within 2 minutes of alignment, including an adhesive 'glue' while a germ tube is formed^{12, 18}. Along with the adhesive glue, degrading enzymes are released from the zoospore to aid in the mechanical penetration of the outer root surface by the germ tube¹².

While zoospore encystment takes a short time (< 10 minutes), full germination takes up to half an hour. The alignment of the zoospore allows for the germ tube to penetrate between the epidermal cells below the spore¹⁸. Once the infection has been initiated, hyphae from the encysted spore are able to divaricate throughout the root tissue¹², and form a variety of terminal hyphae that allow for nutrient uptake. These include intercellular and trans- or intracellular haustoria-like hyphae¹⁸. An established mycelial infection is the primary cause of plant death. Most *Phytophthora* infect at the roots. An established infection causes symptoms like root rot and/or collar rot. These symptoms are caused by a lack of nutrients and water being transported throughout the plant. Eventually the infected plants wither and die²¹. *P. agathidicida* is an aggressive pathogen, capable of infecting all kauri of all ages, including seedlings, rickers, and the larger mature trees.

Lastly, oospores are the thick-walled, durable, dormant, sexual survival spore of many *Phytophthora*^{12, 13, 15, 17}. *Phytophthora* species can form these sexual structures of two classes, either by self-fertilisation if they are homothallic, or by the interaction of opposite mating types, as in heterothallic species^{9, 12, 18, 20}. *P. agathidicida* falls into the homothallic category. This is unlike *Phytophthora infestans* – the causal agent of potato blight – which is heterothallic, and requires both A1 and A2 types to reproduce sexually.

Historically, the mating type A1 spores were geographically separated (Finland/Norway) by the Atlantic ocean from the A2 mating type (Mexico)²². Now, populations of A1 and A2 *P. infestans* are being reported in the same geographical

space, allowing the production of the hardy survival oospores making control of potato late blight even more difficult. These two mating types have spread due to human influence and migration²². Oospores can persist in the environment for long periods until conditions are favourable for germination, leading to new mycelial growth, the development of sporangia and the eventual release of zoospores⁹. This allows *Phytophthora* species to infect crops in successive seasons or colonise replanted trees years later.

1.3 Treatments

The international standard for treatment is a phosphite based agrichemical, or a traditional fungicide. Recently there has been a scientific push to generate new treatment options. DuPont developed a compound called oxathiapiprolin, that specifically targets oomycete oxysterol binding proteins²³.

Mātauranga Māori is the idea to take the knowledge, education, perspective, and creativity of the Māori culture and incorporate this idea into an area of research²⁴. Our kaupapa (action plan) uses mātauranga Māori herbal medicine and customs to find natural product and plant-based metabolites from sources in the local forest environment^{24,25}.

Our Māori collaborators shared a variety of plants that are used in traditional medicine.

Using these plants, previous members of our laboratory made root and leaf extracts and tested these complex mixtures against all the life cycle stages of *P. agathidicida*. Two of the most promising compounds for mycelium inhibition were isolated from extracts of tawhero and patē.

1.3.1 Phosphite Agrichemicals

Phosphite is a well-known agrichemical, that first arrived on the market in the late 1970s and has been used widely ever since²⁶. It is a dual-action agrichemical;

playing a role in the upregulation of plant defence systems and directly inhibiting *Phytophthora* ²⁷⁻³³. Recent reports suggest *Phytophthora* species, *P. cinnamomi*, *P. citrophthora*, *P. syringae*, and *P. parasitica*, are developing tolerance to phosphite treatments and phosphite agrichemicals ^{28, 34}.

1.3.1.1 Plant Defence Systems

Unlike the mammalian immune system, plants do not have mobile immune cells. Instead, they rely on localised response and cell to cell communication at the site of infection. However, like the mammalian immune system, plant cells do recognise pathogen-associated molecular patterns (PAMPS).

PAMPS are recognised by the Pattern Recognition Receptor proteins (PRR) in the intracellular space ³⁵. Once the pathogen is recognised, internal cellular 'R' genes are activated by Nucleotide Binding Site - Leucine-rich repeat proteins (NBS-LRR) ³⁶. R-genes are disease resistance genes ^{35, 36}. The NBS-LRR proteins are considered to be the adaptive plant response to pathogen attack and interact with R-genes for regulation ³⁵.

The immune system acts in four phases ³⁶. The first of these is PAMP-triggered immunity. After a PAMP is recognised and the PRR is activated, a signalling cascade causing the second messenger molecules and NBS-LRR to begin to regulate the plant response to the immune system ^{29, 35, 36}. As the infection progresses, there is a plant versus pathogen struggle. *Phytophthora* species and other plant pathogens (*Bulmeria grammis*, *Puccinia triticina*, and *Fusarium oxysporum*³⁷) have developed ways to suppress the plants' immune system ³⁶⁻³⁸. For example, *Phytophthora* can silence genes of *Arabidopsis* through the use of small interfering RNA. At the same time, *Arabidopsis* is also able to affect *Phytophthora* transcription using the same mechanism ³⁸.

Phosphite affects the plant immune system by priming it for the host-pathogen interaction. Phosphite-based agrichemicals are sprayed onto the leaf surface or injected directly into the trunk. Phosphite is transported through the phloem to the roots, which are the site of action. Phosphite primes the immune system by

upregulating second messengers and reactive oxygen species. Upregulated pathways include jasmonic acid, salicylic acid, and abscisic acid production ²⁹.

An invading *Phytophthora* infection causes plant cytoskeleton and cell wall changes. These cytoskeletal changes enable cells to release a more substantial amount of reactive oxygen species and second messengers. The changes also allow for the production of pathogen-related (PR) proteins ²⁹ and anti-pathogen microRNA ³⁸.

1.3.1.2 *Phytophthora* Inhibition by Phosphite

The mode of action for phosphite inhibition in *Phytophthora* species is complex and several studies have explored this ^{30, 39-45}. Phosphite and phosphate have a similar chemical structure (Figure 1.2). Phosphite is a competitive inhibitor for phosphate transport systems and hijacks these systems to get into cells ⁴⁰. The inhibitory effect is even more pronounced when *Phytophthora* is in a phosphate starved environment ^{30, 41}. Transport across the membrane is pH-dependent ⁴⁰. There are two phosphate transporters in *Phytophthora*; a constitutive active low-affinity transporter and a high-affinity transporter that is induced only when phosphate is limited. Phosphite is believed to be a competitive antagonist for the phosphate transport itself ⁴².




Figure 1.2 Chemical structure of phosphate and phosphite oxyanion.

The chemical structure of both phosphate and phosphite are similar. In their anionic state above they have the same chemical charge. However they do not contain the same of oxygen atoms.

Once the phosphite is taken into the cell, it affects lipids, free fatty acids, diacylglycerol, phospholipase and tri-glycerols/wax esters. There is an increase in the phosphite abundance in lipids in a chloroform extraction. This abundance increase could be attributed to the cell wall structures. This change was also attributed to an increase in the membrane fluidity and permeability ³⁹.

Polyphosphate and pyrophosphate synthesis have been explored as another possible mode of action ⁴³⁻⁴⁵. Phosphate depletion and phosphite transportation could not account for the level of growth inhibition alone ⁴⁵. However, a reduction in glycolysis and change in adenosine triphosphate (ATP) abundance when *Phytophthora* was treated with phosphite is partly accountable for this growth inhibition. There was no corresponding replenishment of ATP after phosphite treatment ⁴². ATP depletion also causes an increase in polyphosphate and pyrophosphate synthesis. This increased ATP consumption, coupled with phosphite incorporation into the glycolysis pathway ⁴³, is attributed to the inhibition of *Phytophthora* species ³⁹.

While a definitive mode of action has yet to be confirmed, it has been made clear that phosphite does change gene expression in various *Phytophthora* species. When *P. cinnamomi* is grown in medium with 40 µg/mL phosphite, 16 essential genes are up-regulated. These included 5 ADP-ribosylation factor genes and a glycosyltransferase ³², which can be attributed to an increase in ATP use. The 27 down-regulated genes included many cellulose synthases, phosphopyruvate dikinases, glucose transporters, and alternative oxidase ³². These changes in gene expression and reduction in biosynthetic pathways (including the cellulose/cell wall pathway) can lead to lysis of the cell and to a change in hyphae morphology.

Phytophthora species have an increasingly devastating impact on agriculture annually. *P. infestans*, the cause of potato late blight, annually causes a \$6.7 billion USD loss in revenue alone ⁴⁶. *P. infestans*, *P. sojae*, and *P. capsici*, have developed resistance and cross-resistance to traditional fungicides currently used in agriculture ⁴⁷⁻⁵³. In citrus orchards in California, USA, *P. parasitica* and *P. citrophthora*, have all begun to show signs of tolerance to phosphite ³⁴. Hunter (2018)⁵⁴ explored the

relative sensitivity of *Phytophthora* isolates to phosphite. There is a co-existence of highly tolerant and sensitive cohorts within isolates of the same *Phytophthora* species⁵⁵. With the emergence of resistance to traditional fungicides and phosphite tolerance there is a push to find new alternative treatment options.

1.3.2 Oxathiapiprolin

A new piperidinyli thiazole isoxazoline core-based compound, oxathiapiprolin, was developed to combat plant pathogens (Figure 1.3). This critical new chemical was optimised to target oomycetes specifically²³. It has been shown to target most of stages of the life cycle stages of *P. infestans*, *P. capsici*, and *P. sojae*. For example, against *P. capsici*, 50% inhibition of growth (EC₅₀) by oxathiapiprolin was of 5.61×10^{-4} µg/ml^{56,57}. Armstrong¹⁹ confirmed that oxathiapiprolin was also highly active against *P. agathidicida*. This study reported an EC₅₀ of 0.14×10^{-4} µg/ml for inhibition of mycelial growth.




Figure 1.3 1-(4-{4-[5-(2,6-difluorophenyl)-4,5-dihydro-3-isoxazol-5-yl]-2-thiazol-5-yl}-1-piperidinyli)-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone (oxathiapiprolin), sold commercially as Zorvic or Segovis.

The oxysterol binding protein-related proteins (ORPs) were revealed as the target of oxathiapiprolin through the use of affinity chromatography and mass spectrometry methods²³. In *Phytophthora*, ORPs are multi-domain proteins that contain a pleckstrin homology (PH) domain, the oxysterol-binding domain (ORD) and a StAR-related lipid-transfer (START) domain superfamily member. The functions of ORPs are still unknown in *Phytophthora* and are currently under exploration⁵⁶⁻⁵⁹. However, research has been conducted on the human and yeast oxysterol binding proteins

(OSBP). These have been implicated in cell cycle regulation, lipid metabolism and transport ⁶⁰⁻⁶².

The Kes1/Osh4 ORP in yeast, *Saccharomyces cerevisiae*, is well-studied, with several known functions. Kes1/Osh4 is the most abundant ORP in *S. cerevisiae* ⁶³. Kes1/Osh4 has been implicated in cell cycle regulation via the Sec14 pathway. Kes1/Osh4 is regulated by PI(4)P phosphoinositol signalling and is involved in transfer of oxysterols to the late golgi complex. Kes1/Osh4 is believed to function directly through ARF1 GTPase nucleotide binding and hydrolysis. Kes1/Osh4 activity is dependent on phosphatidylinositol 4-kinase 1 (Pik1). Kes1/Osh4 signalling leads to the inhibition of golgi secretions and is a cell cycle arrest point ^{62, 64}.

A high resolution crystal structure of the Kes1/Osh4 protein has been solved. This is a relatively short protein, and contains only a oxysterol binding domain (ORD) ⁶⁵. However the ORD usually contains two multi-strand antiparallel β -sheets, forming a nearly complete β -barrel with a characteristic cap to the binding domain ^{62, 64, 66}.

1.3.3 Polygodial

Polygodial is a known, isolated natural product (Figure 1.4). Previously it was isolated from *Warburgia stuhlmannii* and *W. ugandensis* ⁶⁷. Our Mātauranga guided search isolated polygodial from *Weinmannia silvicola* (tawhero) (S. Lawrence, unpublished data). Polygodial has also been found in horopito (*Pseudowintera axillaris*) ⁶⁸.

Many of the sources of polygodial have been from traditional folk medicine. Māori traditionally use horopito for gastrointestinal distress as an antidiarrheal, for aches and pain ⁶⁹, and topically for yeast and ringworm infections ⁷⁰. Parts of tawhero are used traditionally for thoracic and abdominal pain and as a laxative ⁷¹.

The mode of action of polygodial is not fully understood and complex. Polygodial primarily works through disrupting the electrochemical gradient across a phospholipid membrane. This leads to a change in permeability of the plasma membrane ⁶⁷. The electrochemical gradient of the plasma membrane is unable to be restored by the plasma membrane ATPases (PMA1) as it is affected by polygodial ⁷².

Addition to plasma membrane disruption, the mitochondrial electrochemical gradient is disrupted ⁷², this change causes the uncoupling of the electron transport chain, and ATP synthesis ⁷³.




Figure 1.4 The chemical structure of the natural product polygodial

Polygodial is known to be synergistic with other antimicrobial compounds. The synergistic effect of polygodial was looked at using anethole and ethylenediaminetetraacetic acid (EDTA), respectively ^{74,75}. Anethole antimicrobial activity was not enhanced in yeast experiments. However, a combined solution of polygodial and EDTA solution decreases the minimum inhibitory concentration (MIC) of polygodial treatment of *S. cerevisiae* from 3.12 µg/mL to 0.78 µg/mL.

Polygodial's antifungal properties have led to studies that include a general assortment of plant pathogens. This includes *P. infestans* ^{68,76}, and *P. nicotiana* ⁷⁷. Horopito ethanol extracts had in vitro activity against *P. infestans* ⁶⁸. This presents an innovative opportunity to explore the anti-*Phytophthora* activity of polygodial against *P. agathidicida*.

1.3.4 Falcarindiol




Figure 1.5 The chemical structure of the natural product falcarindiol

Falcarindiol can be found in many species of plants in the *Apiaceae* and *Araliaceae* families. Falcarindiol is constitutively active in many plants, including parsnips and carrots (Figure 1.5). This indicates that falcarindiol is one of the primary defence mechanisms to prevent infection in a range of vegetables⁷⁸. Falcarindiol is the compound that gives the bitter taste to carrots.

Many of the *Apiaceae* and *Araliaceae* plant families are used in Russian,⁷⁹ Dutch⁸⁰ and traditional Māori medicines. Falcarindiol was identified in an extract from *Schefflera digitata*, the patē tree (S. Lawrence, unpublished data), which is traditionally used by Māori as medicine. The sap of the patē tree is used to treat skin infections. Diethyl ether crude extracts from patē have been shown to be mildly antimicrobial⁷⁰. The medicinal properties of falcarindiol are diverse. They include antifungal, antioxidant, anticancer, cytotoxic, and immunosuppressive properties, though the underlying mechanisms and cellular targets are still under exploration.

The anticancer and antiproliferative properties of falcarindiol help reduce colorectal tumour growth. Low concentrations of falcarindiol arrest the cell cycle in cancer cell lines at S phase, while higher concentrations cause cellular arrest in the G2/M phase⁸¹. A gastrointestinal mutagenic study shows that falcarindiol was protective against two food preservatives, that are known to be gastrointestinal carcinogens.

Falcarindiol suppressed the SOS signal transduction pathway in the carcinogen study⁸².

Falcarindiol was also found to not have any allergenic activity compared to other polyacetylenes (PA) compounds. It has anti-inflammatory properties and inhibits platelet aggregation which act by inhibiting lipoxygenases and by COX-1 inhibition that modulates the prostaglandin pathway in inflammation⁸³.

While falcarindiol is known to be an antimicrobial agent the current literature does not reflect any anti-*Phytophthora* activity. The addition of falcarindiol to anti-*Phytophthora* agents has led to a promising new development in the fight against kauri dieback, and the *Phytophthora* genus.

1.4 Antimicrobial Resistance

There is a well characterised mechanism for antimicrobial resistance in microbial systems. Antibacterial compounds target critical cellular mechanisms. The use of traditional fungicides for the treatment of *Phytophthora* has led to resistance development. Mandipropamid treated *P. infestans* infections have already led to a resistance mutation in the PiCesA cellulose synthase⁸⁴. More recently, a C239S mutation in the β -tubulin of *P. sojae* has conferred resistance to zoxamide⁴⁷. Additionally metalaxyl and phenylamide treatments have led to cross-resistance for other traditional unrelated fungicides^{49, 52, 85}.

1.4.1 Phosphite Resistance

Phosphite is the gold standard in the treatment of *Phytophthora* diseases; however, resistance or tolerance is an emerging risk. Adaskaveg (2017)³⁴ and Hunter (2018)⁵⁴ have looked at the increasing amount that is required to control *Phytophthora* infection in citrus fruit^{34, 54}. Hunter (2018)⁵⁴ notes a high level of variability between geographical isolates of the same species.

1.4.2 Oxathiapiprolin Resistance

As of 2012, the Chinese government requires resistance assessments of novel pesticides, to explore the potential of resistance. Therefore, a resistance assessment was performed on *P. capsici* isolates^{56,57}. Serial plating was used to isolate *P. capsici* variants that showed higher growth rate after treatment with oxathiapiprolin^{23,57}. All of the tolerant *P. capsici* variants showed mutations within the oxysterol-binding domain (ORD) of the ORP²³. One such mutation was G769W in the *P. capsici* ORP1 protein⁵⁶.

1.5 Aims of this Research:

The research in this thesis aimed to investigate the resistance and sensitivity of *P. agathidicida* towards existing and novel treatments. This may yield insights into disease management in New Zealand kauri forests, as current studies focus on pathogen control but do not address how long a treatment is likely to work.

1.5.1 Aim 1

The addition of another quantitative data set on the direct toxicity of phosphite towards *P. agathidicida* was explored in this research. A comparison of all three commercial preparations of phosphite (Agri-Fos 600, Foschek and Phosgard), and a pure sodium phosphite salt was performed to determine the EC₅₀. The contribution of the adjuvants and surfactants, in the commercial preparations were also assessed as they may contribute to toxicity.

1.5.2 Aim 2

A risk assessment was undertaken to determine the likelihood of antimicrobial resistance to phosphite, polygodial and falcarindiol in *P. agathidicida*. An adapted protocol for evolving oxathiapiprolin resistance⁵⁶ was used for sodium phosphite and the natural products. The final evolution rounds were compared to the parental isolate and a sensitive isolate of *P. agathidicida* isolates.

1.5.3 Aim 3

The *P. agathidicida* ORP1 (PaORP1) gene was identified and compared to orthologues from other Phytophthora species. The *PaORP1* gene was amplified for five isolates of *P. agathidicida* and assessed for genetic diversity.

1.5.4 Aim 4

A protocol was developed for expression and purification of PaORP1 ORD protein. This protocol was developed to express a wild type PaORP1 domain, and an equivalent resistance tryptophan mutant domain - PaORP1 G771W. These two ORP1 domains were cloned, expressed and purified in *Escherichia coli*.

Chapter 2

Materials and Methods

2.1 Materials

2.1.1 General Materials

General chemicals, such as calcium carbonate (CaCO₃), were purchased from Sigma Aldrich Inc, (St. Louis, MO, USA) and Thermo Fischer Scientific (Waltham, MA, USA), Unless stated otherwise. Restriction enzymes and their buffers were from New England Biolabs (water was deionized and filtered by Milli-Q Integral Water Purification System (EMD Millipore, Billerica, MA, USA). Solutions and media were sterilised by autoclaving (at 121 °C, 100 kPa for 15 min) in a Systec-D series benchtop autoclave (Linden, Germany).

2.1.2 *Phytophthora agathidicida* Isolates

All *P. agathidicida* isolates used were provided by the Healthy Trees, Healthy Future Research Programme, Scion, Rotorua, New Zealand ⁸⁶ (Table 2.1). Unless stated otherwise, all work on *P. agathidicida* was conducted on isolate NZFS 3770.

Table 2.1. *Phytophthora agathidicida* isolate ID reference numbers, locations and year collected.

Species	Isolate	Location	Year
<i>Phytophthora agathidicida</i>	NZFS 3770	Great Barrier, New Zealand	2006
	NZFS 3772	Coromandel, New Zealand	2013
	NZFS 3813	Coromandel, New Zealand	2014
	NZFS 3814	Coromandel, New Zealand	2014
	NZFS 3815	Coromandel, New Zealand	2014

The draft genome of *P. agathidicida* isolate 3772 was downloaded from GenBank (accession number LGTR000000000.1) ⁸⁶.

2.1.3 Bacterial Strains.

Protein expression and cloning experiments were conducted with the bacterial strains presented in Table 2.2.

Table 2.2 Bacterial strains and their associated genotype.

<i>E. coli</i> strain:	Genotype	Source
BL21-(DE3)-gold	ompT gal dcm lon hsdSB(rB- mB-) λ(DE3 [lacI lacUV5-T7 gene 1 ind1 sam7 nin5])	Agilent
<i>E. coli</i> 10G	F- mcrA Δ(mrr-hsdRMS-mcrBC) endA1 recA1 Φ80dlacZΔM15 ΔlacX74 araD139 Δ(ara,leu)7697 galU galK rpsL nupG λ- tonA	Lucigen

2.1.4 pET28 Plasmid

The plasmids were designed using SnapGene software and the plasmid construct was produced by Twist Bioscience (San Francisco, CA, US). The plasmid map (Figure 2.1) shows the general construct. Two variants were produced by Twist. A wild type variant (PaORP1_wt) and a mutant variant (PaORP1_771W) (Table 2.3). These were shipped as dry pellets and resuspended in TE buffer (Tris, and Ethylenediaminetetraacetic acid at pH 7) to a 50 ng/μL concentration.




Figure 2.1 pET28 plasmid with PaORP1 DNA insert.
 This DNA insert is Histidine tagged (6x his) and TEV cleavage site before the *P. agathidicida* ORP1 sequence. Knp1 restriction site was introduced into the plasmid.

Table 2.3 PaORP1 DNA insert of wild type and mutant variants

PaORP1 inserted DNA into pET28 plasmid	
PaORP1_wt	<p>GCCAAGAAGCAGGGTGGCGTGGTGAAGGATGTCATCAAATCGGCAG GAGCAAAAATCCTGGAGGGCAAGTCGGCTGTGAGTCTATCGCTGCC TGTGCGTATTTTCGAGCCTCGCACCAATCTGGAACGTGTGTGCGATTT AATGCTGTACGCGCCGACGTTCCCTGAACGTTGCACACGCGCAGAAC GATGCTTTAGAGCGATTCAAGTACGTCATGACATTTGCCGTGGCTGG TCTGCACCACAGTATTGGACAGTTGAAGCCGTTTAACCCCATCTTGG GTGAGACGTTCCAGTCTACGCTGAACGATGGTACAGATGTAAGTTGC GAACACACGAGCCATCACCCGCCTATCAGTAACTTCCAGTTCACCCGG AGAAAAGTACTCCATCGCTGGTTTTGTGCTGTGGCATGCGAGCATGA GCGTGAAGTCGAATGCAATGCTCAACACAAACAAGGGGCCTGTGCG CGTGACGTTCCCCGACTCTGAAGGCCTTCCTGGAACGACCATCGAG TACAACCTACCGTACTTGCAGATTGGTGGGTTGCTTTGGGGAGACCG TACCGTTGACATCATGGGGAATATGGTGTGTTGAAGACAAGAAGAACC ATCTACAGTGCGAACTGCGCCTCAATCCGGATGCCAAGTCAGGAATG GGCGGAATGTTTTCTAGCTCTAAAACCCCGACGGATTTCGTTGCGTGG TGTGATCTTGGACACTTCTGTGTCTCCACCGCGTGAGATTTGTGACGT CTCGGGCTCCTGGCTGCATGACCTCGTGTTCGGCAACAAGACGTAC TGGAGCATCAACAAACACCACAGCGGCTACATGGTACCGTACCCCG AGAACAAGATTTTGGCGTCCGACTCTCGGTACCGCGAAGACCTGCA CTATCTGGCAGCAGGCGACCTGGATGAATCGCAAGAGTGGAAGGTA AAGCTGGAGGTTCTGCAGCGCGCTGATCGCAAGGCGCGTCTGGACG GC</p>
PaORP1_G771W	<p>GCCAAGAAGCAGGGTGGCGTGGTGAAGGATGTCATCAAATCGGCAG GAGCAAAAATCCTGGAGGGCAAGTCGGCTGTGAGTCTATCGCTGCC TGTGCGTATTTTCGAGCCTCGCACCAATCTGGAACGTGTGTGCGATTT AATGCTGTACGCGCCGACGTTCCCTGAACGTTGCACACGCGCAGAAC GATGCTTTAGAGCGATTCAAGTACGTCATGACATTTGCCGTGGCTGG TCTGCACCACAGTATTGGACAGTTGAAGCCGTTTAACCCCATCTTGG GTGAGACGTTCCAGTCTACGCTGAACGATGGTACAGATGTAAGTTGC GAACACACGAGCCATCACCCGCCTATCAGTAACTTCCAGTTCACCCGG AGAAAAGTACTCCATCGCTGGTTTTGTGCTGTGGCATGCGAGCATGA GCGTGAAGTCGAATGCAATGCTCAACACAAACAAGTGGCCTGTGCG CGTGACGTTCCCCGACTCTGAAGGCCTTCCTGGAACGACCATCGAG TACAACCTACCGTACTTGCAGATTGGTGGGTTGCTTTGGGGAGACCG TACCGTTGACATCATGGGGAATATGGTGTGTTGAAGACAAGAAGAACC ATCTACAGTGCGAACTGCGCCTCAATCCGGATGCCAAGTCAGGAATG GGCGGAATGTTTTCTAGCTCTAAAACCCCGACGGATTTCGTTGCGTGG TGTGATCTTGGACACTTCTGTGTCTCCACCGCGTGAGATTTGTGACGT CTCGGGCTCCTGGCTGCATGACCTCGTGTTCGGCAACAAGACGTAC TGGAGCATCAACAAACACCACAGCGGCTACATGGTACCGTACCCCG AGAACAAGATTTTGGCGTCCGACTCTCGGTACCGCGAAGACCTGCA CTATCTGGCAGCAGGCGACCTGGATGAATCGCAAGAGTGGAAGGTA AAGCTGGAGGTTCTGCAGCGCGCTGATCGCAAGGCGCGTCTGGACG GC</p>

2.1.5 Agrichemicals

Four commercially available phosphite solutions were obtained. Agri-Fos 600 (Agrichem, Queensland, AUS) had previously been purchased by another member of the laboratory¹⁹. Foschek, a phosphite-less version of Foschek (Lonza, New Plymouth, NZ) and Phosgard (Grochem, Wellington, NZ), were donated by the manufacturers. The supplied stocks contained phosphite at 400 g/L or 600 g/L, and were then diluted with water to working stocks of 1 mg/mL or 20 mg/mL. Sodium phosphite (Sigma Aldrich Inc) was dissolved in deionised water, to the same working stock concentrations of 1 mg/mL or 20 mg/mL. All commercial agrichemicals were sterilised by filtration through a 0.22 µm membrane before use.

2.1.6 Antibiotics and Natural products

Kanamycin was supplied by Thermo Fisher Scientific. Kanamycin was prepared to a concentration of 30 mg/mL by dissolving in Milli-Q deionised water and then filter sterilised. All the antibiotics were syringe filtered through a 0.22 µm filter (Jet Bio-Filtration Co. Ltd, GZ, China) were then stored at -20 °C and thawed for use.

Falcarindiol (purchased from Biosynth Carbosynth, Berkshire, UK) was dissolved in 100 % dimethyl sulfoxide (DMSO) to a stock concentration of 1 mg/mL and 5 mg/mL. Polygodial (purchased from Biosynth Carbosynth Berkshire, UK) was dissolved in DMSO to 1 mg/mL or 5 mg/mL, then stored at -20 °C and thawed for use.

2.1.7 PARP Agar

PARP agar plates were prepared by mixing 17 g of pre-formulated cornmeal agar (Difco™) with 1 litre of water. Media were autoclaved and cooled to approximately 60 °C or until the container was warm to the touch and able to be held, before adding the antibiotics and fungicides (Table 2.4). Petri dishes were filled with approximately 20-25 mL of molten agar using aseptic techniques. Once solidified, the agar plates were wrapped in foil, and stored in the dark at 4 °C.

Table 2.4. Component volumes and concentrations of PARP agar ingredients

Per litre:	Ingredients	Final Concentration
17 g	Cornmeal agar (Difco™)	
500 µL	Amp (500 mg/mL stock)	250 µg/mL
500 µL	Rifampicin (20 mg/mL, dissolved in DMSO or acetone - stock stored - 20°C)	10 µg/mL
400 µL	Pimaricin (2.5% solution, stored 4°C - resuspend by pipetting before using).	10 µg/mL
2.5 mL	Pentachloronitrobenzene* (PCNB) 40 mg/mL, dissolved in DMSO with vortexing - made fresh.	100 µg/mL

2.1.8 V8 Agar

To prepare V8 broth, 100 mL of Original V8 Juice (Campbell Soup Company) was diluted with 150 mL of water. 1 g CaCO₃ was added to adjust the pH to approximately 7.0. Once the pH was adjusted the broth was made up to 1 L. Then 15 g of agar (Formedium™) was added per litre of broth, before sterilisation by autoclaving. The agar was cooled until the container was warm to the touch and able to be held. Plates containing approximately 20-25 mL of agar were poured using standard aseptic techniques. Freshly poured plates were allowed to cool and dry under a Bunsen flame for at least 30 min. Once solidified, agar plates were stored at 4 °C in the dark ⁸⁷.

2.1.9 Potato Dextrose Agar (PDA)

Premixed potato dextrose agar (Difco™) was used to make and pour PDA plates. 39 g of powdered premix was dissolved in 1 L of deionised water before sterilised by autoclave. The agar was cooled until the container was warm to the touch and able to be held. Plates containing approximately 20-25 mL of agar were poured using standard aseptic techniques. Freshly poured plates were allowed to cool and dry under a Bunsen flame for at least 30 min. Once solidified agar plates were stored at 4 °C.

2.1.10 Carrot Broth

50 g of carrot and 100 mL of deionised water were blended using a George Foreman Mix & Go Classic blender (Spectrum Brands, WI, USA). 1 g of CaCO₃ was added to adjust the pH to approximately 7.0. Once the pH was adjusted, the broth was made up to 1 L before being sterilised by autoclave.

2.1.11 Terrific Broth

Terrific broth was made up to 1 L in a 2.5 L Ultra Yield™ flask, (Thomson Instrument Company) using 47.6 g of premixed terrific broth powder (Formedium™) dissolved into 1 L Milli-Q deionised water. This solution was autoclaved to become sterilised before inoculating with a bacterial culture.

2.1.12 Auto Induction Medium

55.85 g of premixed autoinduction medium powder (Formedium™) was dissolved in 1 L deionised water, in a 2.5 L Ultra Yield™ flask (Thomson Instrument Company). 8 ml of 50 % glycerol was added to the autoinduction medium before the solution was sterilised by autoclaving. The appropriate antibiotic was added (1:1000 dilution) once the solution was cool to the touch or at room temperature.

2.1.13 LB Broth

6.25 g of premixed, powdered LB broth Miller (Formedium™) was dissolved in 250 mL of deionised water before being sterilised by autoclave. This was then used for routine overnight culturing of *Escherichia coli*.

2.1.14 PCR Primers

Primers (Table 2.5) were designed for the *P. agathidicida* ORP gene sequence using SnapGene software. Primers were supplied by Macrogen (South Korea). The GK4 primers in Table 2.5 were for PCR controls and were designed previously¹⁹. All primers were resuspended in TE buffer (Tris, and EDTA at pH 7).

Table 2.5 Polymerase chain reaction primers and melting temperatures

Primer	Sequence (5' → 3')	T _M
PTA_OSBP_For_1	CGGCTTATTTCTTGCCTGCCCGCTG	66 °C
PTA_OSBP_For_2	CCAATTCCAGCAGTTCTGCACCGTCGTC	66 °C
PTA_OSBP_For_3	GTGGCTGCAGCGGCGTGCG	69 °C
PTA_OSBP_For_4	TGGCGTGGTGAAGGATGTCATC	61 °C
PTA_OSBP_Rev_1	TACGCTTGCTTTTCGCTGGTTATCGCAGAG	66 °C
GPCR_GK4 Forward	ATTGGATCCATGGCGGTGTGCGCGCCCGAGACG GC	74 °C
GPCR_GK4 Reverse	CGCAAGCTTCTATATCTCCATTGAGAGGTTGGAGT CCAATGAGACGTTTCG	71 °C

2.1.15 Protein Purification Buffers

All buffers (Table 2.6) were prepared using Milli-Q deionised water. Each buffer was made to 500 mL or 1 L and stored at 4 °C. Each buffer was pH adjusted before being made up to a final 500 mL or 1 L stock solutions. 5 mM β-mercaptoethanol was added to 100-150 mL aliquots of buffer, as needed for each purification. These solutions were vacuum filtered using a 0.22 µm filter disc, degassed and then stored at 4 °C.

Table 2.6. Protein purification buffer components.

Lysis Buffer (pH 7.8)	Elution Buffer (pH 7.8)	Size Exclusion Buffer (pH 5)
50 mM HEPES,	50 mM HEPES,	50 mM Sodium Acetate
300 mM NaCl	300 mM NaCl	150 mM NaCl
10 mM Imidazole	300 mM Imidazole	Acetic Acid
10% Glycerol	10% Glycerol	10% Glycerol
5 mM β-mercaptoethanol	5 mM β-mercaptoethanol	5 mM β-mercaptoethanol
0.5% Tween-80		

2.1.16 Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE)

SDS-PAGE was used to visualize and separate the proteins based on size. The components to make SDS-PAGE gel are shown in Table 2.7. Glass plates were aligned and held together within a plastic multi caster system (Bio-Rad, Hercules, CA, USA). The resolving gel was poured between the plates until the solution was approximately 2 cm from the top, then 70% (v/v) ethanol was overlaid to prevent dehydration and to level the top of the resolving gels. After approximately 1 h, polymerisation of this resolving gel was complete and the ethanol was rinsed off with distilled water. The stacking gel was then poured on top and a 15 well, 1 mm comb was inserted into the liquid gel. Once polymerisation had taken place, the gel was wrapped in damp paper towels and placed into a plastic bag. The gel was stored at 4 °C to prevent dehydration from occurring.

Table 2.7. Components for pouring 10 SDS-PAGE gels.

Components of SDS Gel	Resolving	Stacking
1.5 M Tris-HCl pH 8.8	16.5 mL	
0.5 M Tris-HCl pH 6.8		6 mL
Milli-Q water	28.7 mL	15.2 mL
SDS (10% (w/v))	660 µL	240 µL
40% solution, 29:1 acrylamide : bis-acrylamide	19.8 mL	2.4 mL
Ammonium persulfate (10% (w/v))	330 µL	120 µL
Tetramethylethylenediamide	66 µL	24 µL

2.2 Methods

2.2.1 Routine Agar Culturing

P. agathidicida was routinely cultured on V8 agar. A plug of agar (~5 mm) containing *P. agathidicida* mycelia was placed centrally on a V8 agar plate (standard petri dish 90 mm diameter). After 5-7 days incubating at 22 °C in darkness, a plug of agar was removed from the leading edge of the mycelial mat and placed on a new V8 agar plate.

After culturing on agar 6-8 times, it is standard practice for *Phytophthora* cultures to passage through plant tissue to preserve the pathogenicity⁸⁷. For *P. agathidicida*, a plug of agar from the leading edge of the mycelial growth was passaged through a pear according to standard protocols⁸⁷. Briefly, the plug of mycelium was placed in a pear and incubated for approximately 7 days at 24 °C. A small section (5 mm diameter) from the pear was then cut from the advancing section of rot and placed on selective PARP agar to re-isolate *P. agathidicida*⁸⁸. The plates were incubated at 22 °C for 5-7 days. Once *P. agathidicida* mycelia had grown on PARP, the incubation on V8 agar restarted and the culturing cycle continued.

2.2.2 Broth Culturing

A plug of V8 agar (~5 mm) containing *P. agathidicida* mycelia was placed in a tube containing, 30 mL of carrot broth or potato dextrose broth. The mycelial mat was used after 5 days of growth.

2.2.3 Amended Media

An agrichemical was added to molten potato dextrose agar at about 60 °C. Plates (60 mm diameter) containing approximately 10 mL of agar were poured using standard aseptic techniques. Freshly poured plates were allowed to cool and dry under a Bunsen flame for at least 30 min. Once solidified, agar plates were stored at 4 °C in

the dark until inoculated with a 2.5 mm *P. agathidicida* plug. Once inoculated, the plates were grown for 5 days at 22 °C.

2.2.4 In Vitro Growth Assays

After 5 days of growing at 22 °C, the sizes of mycelial mats were measured using ImageJ software⁸⁹. A positive control plate (potato dextrose agar only) was also inoculated with a 2.5 mm *P. agathidicida* plug, to set a baseline for 100% growth. Agrichemical concentrations in the amended plates ranged from 0.1 µg/mL to 200 µg/mL. The overall diameter of the mycelial mat was measured, the centre was found, then 6 measurements of radial growth were obtained. The average radial growth at each agrichemical concentration was squared to give a relative area of mycelial growth. EC₅₀ values were calculated using linear regression in Prism GraphPad version 8.0.

2.2.5 Serial Passaging

For serial passaging, molten agar was amended with a chemical, as previously described in methods 2.2.3. The agar plate was inoculated with a 2.5 mm *P. agathidicida* plug before growing for 5 days at 22 °C. After 5 days, the inoculated media had another amended agar layer added over the top of the current agar plate. This double-layer inoculated agar was grown for another 5 days at 22 °C to allow mycelia to grow up through the overlaid agar containing an inhibitory chemical.

After day 10, a plug was taken from the double layer agar and used to inoculate a new plate amended with a higher concentration of the chemical. This was repeated until there was no growth on the new amended agar.

For long-term storage, 10-15 plug samples (2.5 mm diameter) were taken along the leading edge of the mycelial growth and placed into a 5 mL amber glass vials. The vials were then filled with 3-5 mL of sterile water until the plugs were covered and capped. These vials were stored at room temperature in the dark until further use.

2.2.6 DNA Extraction

A 5 mm plug of *P. agathidicida* was grown in 20% carrot broth for 10 days. The resulting mycelial mat was washed several times with sterile deionised water to remove any carrot broth contamination. Mycelial mats were left to dry in a 37 °C incubator for 30 minutes. DNA was extracted using the Promega Wizard DNA extraction kit and plant extraction protocol, as described previously by Armstrong (2018)¹⁹.

2.2.7 DNA Agarose Gel

DNA obtained from PCR was separated according to size by gel electrophoresis. A 1% agarose gel was made with 1 x TAE buffer (400 mM tris-acetate pH 8.4, 1 mM EDTA, 20 mM acetic acid). DNA was mixed with a loading dye (KAPA Biosystems). A DNA size marker, 1 kb+ Universal Ladder (KAPA Biosystems), was loaded on the gel along with the samples. Gels were electrophoresed in 1 x TAE for 25 minutes at 110 V. Gels were stained using ethidium bromide for 30 minutes after electrophoresis, then rinsed with deionised water. Gels were visualised under a UV light in a UV Tec Geldoc system (Uvitec Ltd, Cambridge, UK).

2.2.8 Polymerase Chain Reaction (PCR)

PCRs made use of KAPA Taq Ready Mix with dye (KAPA Biosystems). Reactions were carried out in a total volume of 20 µL: 10 µL Ready Mix, 0.8 µL Reverse Primer and 0.8 µL forward primer (each primer stock at 10 µM), 1 µL of template DNA (concentration 8 to 120 ng/µL) and 7.4 µL of sterile deionised water. Thermal cycling was carried out in a MultiGene™ Gradient Thermal Cyclers (Labnet International Inc, US), as shown in Table 2.8.

Table 2.8. Pre-programmed thermocycling temperatures.

	Temperature (°C)	Time
Start	94	20 sec
Cycles (30)	94	20 sec
	57	20 sec
	72	3 min
Extension	72	3 min
Hold	10	

2.2.9 DNA Sequencing

Sanger DNA sequencing was carried out by Macrogen (Seoul, South Korea).

2.2.10 Bioinformatics

The draft genome of *P. agathidicida* isolate 3772 was downloaded from GenBank (accession number LGTR00000000.1). The file contained 3000+ contigs. The contig tags were removed using a custom Python script and one continuous sequence was generated. The one continuous sequence was analysed using SnapGene software.

An open reading frame of 3330 bp was found to have the closest sequence identity to the other *Phytophthora* species. A 16 bp motif (GCTCATTYBNNNWTTY)¹¹ surrounds the transcriptional start site of many genes and was located via a find and search method in Snap gene. Exon-Intron junction information was found using this same method and sequence 5' -GTRNGT. . .YAG- 3'¹¹. The intronic sequences were confirmed with a CTAAC motif present between the exon-intron junctions.

Once the PaORP gene was located, SnapGene was used to translate it into a protein sequence. This was checked against the ORP sequences from other *Phytophthora* species reported in Andreassi, Gutteridge, Pember, Sweigard and Rehberg⁹⁰. SWISS-MODEL was used for protein structure prediction⁹¹.

2.2.11 Freezer Stocks

All bacterial strains were permanently stored at -80 °C. Stocks were generated from overnight cultures mixed 1:1 with sterile 50% glycerol.

2.2.12 Overnight Cultures

Overnight cultures were 5 mL of appropriate media with the required antibiotics. Each was grown overnight (16hrs) at 37 °C and aerated by shaking at 180 rpm in an Innova 44 Shaking incubator (New Brunswick Scientific, NJ, US). The media was inoculated using either freezer stock or from a single colony on an agar plate using sterile techniques.

2.2.13 Electrocompetent Cells

A 6 mL overnight culture was divided into 1.5 mL aliquots and harvested by centrifugation at 15,000 xg for 1 minute at room temperature. Each bacterial pellet was washed three times with 1 mL of 300 mM sucrose at room temperature. The pellets were pooled into 2 aliquots of 50 µL. These aliquots could be then used to transform *E. coli* strains with a plasmid (Methods 2.2.14)

2.2.14 Transformation

The pET28 plasmid was added to an aliquot of electrocompetent cells using sterile techniques in a 2 mm MicroPulser electroporation cuvette (Bio-Rad, Hercules, CA, USA). The cells were electroporated with a 2.5 kV electric pulse in the MicroPulser (Bio-Rad, Hercules, CA, USA), after which 500 µL SOC (super optimal broth with catabolite repression) medium (Ready to use, purchased from Thermo Fisher) was added immediately. The cells were recovered for approximately 1 hour at 37 °C and then aliquots were spread on selective agar plates which were incubated overnight at 37 °C.

Colonies that grew on the selective agar plates were used to inoculate 5 mL LB including the appropriate antibiotic and incubated at 37 °C with shaking at 180 rpm overnight. Each culture was made into a freezer stock by mixing an aliquot 1:1 with sterile 50% glycerol and permanently storing at -80 °C.

2.2.15 Enzyme Digest of Plasmid

Diagnostic restriction digests made use of the enzyme combinations NcoI-HF/XhoI and KpnI/XhoI, incubated at 37 °C for 1 h. Each reaction mixture contained 300 ng of plasmid DNA, 2 µL of Cut-Smart buffer and 0.5 µL of each restriction enzyme, made up to a 20 µL volume with sterile deionised water. The products were separated by electrophoresis on a 1% agarose gel and then visualised under UV light in a UV Tec Geldoc system (Uvitec Ltd, Cambridge, UK).

2.2.16 SDS-PAGE

Samples collected from protein expression, purification or size exclusion chromatography (SEC) were mixed at a 1:1 ratio with 2 x SDS-PAGE loading dye (100 mM Tris-Cl at pH 6.8, 4% SDS, 20% glycerol, 0.2% bromophenol blue, 200 mM β-mercaptoethanol). The protein samples were then denatured by heating at 95 °C for 10 min in a MultiGene™ Gradient Thermal Cycler (Labnet International Inc, US). The SDS-PAGE gel was loaded with 5 µL of a molecular weight marker (Bio-Rad, Hercules, CA, USA) and 5 µL of total and soluble protein fractions from the various time points. Electrophoresis was conducted in a Mini-Protean tetra cell system (Bio-Rad, Hercules, CA, USA) at 200 V for 50 minutes in SDS-PAGE running buffer (25 mM Tris at pH 8.3, 250 mM glycine, 0.1% SDS). The separated proteins were visualised with Coomassie blue staining (1.5 M Coomassie R250, 50% methanol, 10% acetic acid) for approximately 30 minutes while gently rocking on a Platform Rocker (Labnet International Inc, US). The stain was then removed, and the gel was transferred into destain (30% methanol, 10% acetic acid) until the gel was sufficiently de-stained and protein bands were visible.

The gel was then visualised under white light in a UV Tec Geldoc system (Uvitec Ltd, Cambridge, UK).

2.2.17 Protein Purification

2.2.17.1 Initial Protocol

An overnight (16 to 18 hrs) culture was used to inoculate TB growth medium (Materials 2.1.11) with 30 µg/mL kanamycin. The culture was placed into an Innova 44 shaking incubator (New Brunswick Scientific, NJ, US) at 37 °C and 180 rpm until an OD₆₀₀ reading of 0.6-0.8 was reached (usually 3.5-4 h). Once the appropriate OD₆₀₀ was reached, Isopropyl β-d-1-thiogalactopyranoside (IPTG) was added to a final concentration of 0.5 mM to induce expression of PaORP1. The induced culture was grown overnight in an Innova 44 shaking incubator at 18 °C.

The following day the cells were harvested by centrifugation at 1500 xg for 20 minutes. The pelleted cells were transferred into a 50 mL tube, weighed and used in the following method, or snap-frozen by liquid nitrogen and stored at -20 °C for later use. The newly transferred cells were resuspended in the first three components of the lysis buffer (Table 2.6) along with the following components in Table 2.9. The cells and solution were vortexed to help resuspend cells and then left to incubate on ice for 30 minutes.

Table 2.9. Resuspending solution components

Component		Concentration
Lysis Buffer (pH 7.8)		5 mL/g of pellet
Lysozyme	20 mg/mL stock	0.5 mg/mL
Benzonase		0.1 µL/g of pellet
Protease inhibitor cocktail (PIC)		20 µL/g of pellet

After incubation, the cells were lysed by sonication (10 s on, 30 s off, 10 cycles, at a power setting no higher than 40%) on ice. The lysate was transferred to a 40 mL centrifuge tube. The lysate, with balance, was centrifuged in a Sorvall LYNX 4000 Superspeed Centrifuge (Thermo Fisher Scientific, USA) to pellet cell debris at

15,000 xg for 60 minutes at 4 °C. Once centrifuged, the lysate was transferred to a clean 50 ml tube, and clarified through 0.45 µm syringe-driven filter, then a 0.22 µm filter (Jet Bio-Filtration Co. Ltd, GZ, China).

Immobilised metal affinity chromatography (IMAC) was done using a nickel His-trap column (1 mL or 5 mL; GE Healthcare Bio-Sciences, PA, USA) on an ÄKTA Start protein purification system (GE Healthcare). The column was washed with degassed and filter sterilised Milli-Q water, and then lysis buffer (Table 2.6). The sample was loaded onto the His-trap column, before contaminants and PaORP1 were eluted over a gradient from 0 to 100% elution buffer (Table 2.6). The gradient was over a total volume of 30 mL. Elution fractions were collected and analysed by SDS-PAGE (Methods 2.2.16 above).

2.2.17.2 Optimised Protein Purification

An overnight (16 hrs) culture was used to inoculate 1000 mL of pre-sterilised autoinduction medium (AIM) (Materials 2.1.12) supplemented with 30 µg/mL kanamycin. The culture was incubated at 37 °C with shaking at 180 rpm in an Innova 44 shaking incubator, until an OD₆₀₀ reading of 0.6-0.8 was reached (usually 3.5-4 h). Once the appropriate OD₆₀₀ was reached, the culture was transferred to a shaking incubator at 18 °C and 180 rpm, and allowed to grow overnight (16 to 18 hrs).

The following day, cells were harvested by centrifugation at 1500 xg for 20 minutes. The pelleted cells were transferred into a 50 mL tube, weighed and used immediately, or snap-frozen in liquid nitrogen and stored at -20 °C for later use. The cell pellet was resuspended in 30 mL of lysis buffer (Table 2.6), along with the following components in Table 2.9. The cells were resuspended by vortexing and then left to incubate on ice for 30 minutes.

After incubation, the cells were lysed by the French press method on ice. The lysate was transferred to a 40 mL centrifuge tube. The lysate, with balance, was centrifuged (Sorvall LYNX 4000 Superspeed Centrifuge) to pellet cell debris at 15,000 xg for 60 minutes at 4 °C. Once centrifuged, the lysate was transferred to a clean 50 mL tube, and filtered through both 0.45 µm and 0.22 µm filters (Jet Bio-Filtration Co.).

IMAC was done as described above (Methods 2.2.17.1) except an isocratic elution method was used instead of a gradient. Four stepwise increments, with increasing imidazole concentrations, were used to elute the protein (Table 2.10). Elution fractions were collected and analysed by SDS-PAGE (Methods 2.2.16 above).

Table 2.10 Isocratic elution steps for His-trap purification on the ÄKTA Start protein purification system.

Step	Lysis buffer	Elution buffer	Column volumes
1	65%	35%	10
2	50%	50%	10
3	20%	80%	5
4	0%	100%	5
		Total	30

2.2.17.3 Protein Concentration

Elution fractions containing the PaORP1 protein were concentrated using an Ultra-15 Centrifugal Filter Unit with 10 kDa molecular weight cut-off membrane (Sigma Aldrich Inc). The unit was centrifuged in a Sorvall LYNX 4000 Superspeed Centrifuge (Thermo Fisher Scientific, USA) 15,000g for 10 minute intervals until the volume was 1-2 mL. The concentration was then measured using a Nanophotometer NP80 (Implen, München, Germany.)

2.2.18 Size Exclusion Chromatography

A Superdex 200 Increase 10/300 GL size exclusion column (GE Healthcare Bio-Sciences, PA, USA) was connected to an ÄKTA Pure protein purification system. The column was equilibrated with degassed and filter sterilised milli-Q water before being washed with size exclusion buffer (Table 2.6). A 500 µL sample of concentrated protein was loaded manually into the same valve, and run isocratically in size exclusion buffer at a flow rate of 0.75 mL/min. Fractions (1.2 mL) that showed a change in absorbance above the baseline at 280 nm were collected and analysed by SDS-PAGE (Methods 2.2.16 above).

2.2.19 Fluorescence Thermal Shift Assay

A thermal shift assay was done using SYPRO Orange Protein Gel Stain (Sigma Aldrich Inc) in accordance with Lo, Aulabaugh, Jin, Cowling, Bard, Malamas and Ellestad⁹². The protein concentration was < 10 μM and used a variety of buffers (Table 2.11) in a 48 well plate (Thermo Fischer Scientific). The final volume in each well was 20 μL , including 2 μL of SYPRO Orange. Thermal melts were performed on a StepOnePlus™ Real-time PCR system (Applied Biosystems™, CA, USA). The 48 well plate was heated from 20 to 90 °C with a heating rate of 0.5 °C/mi.

Table 2.11 Components of the buffer screen and 48-well plate set up.

	1	2	3	4	5	6	7	8
A	50 mM sodium acetate-acetic acid 50 mM NaCl pH 5.0	50 mM sodium MES 50 mM NaCl pH 6.0	50 mM bis-tris chloride 50 mM NaCl pH 6.5	50 mM imidazole 50 mM NaCl pH 7.0	50 mM sodium HEPES 50 mM NaCl pH 7.0	50 mM sodium HEPES 50 mM NaCl pH 7.5	50 mM Tris chloride 50 mM NaCl pH 8.0	50 mM glycl-glycine 50 mM NaCl pH 8.5
B	50 mM sodium acetate-acetic acid 50 mM NaCl pH 5.0	50 mM sodium MES 200 mM NaCl pH 6.0	50 mM bis-tris chloride 200 mM NaCl pH 6.5	50 mM imidazole 200 mM NaCl pH 7.0	50 mM sodium HEPES 200 mM NaCl pH 7.0	50 mM sodium HEPES 200 mM NaCl pH 7.5	50 mM Tris chloride 200 mM NaCl pH 8.0	50 mM glycl-glycine 200 mM NaCl pH 8.5
C	50 mM sodium acetate-acetic acid 200 mM NaCl pH 5	50 mM citrate-citric acid 50 mM NaCl pH 6.0	50 mM ADA * 50 mM NaCl pH 6.5	50 mM sodium MOPS 50 mM NaCl pH 7.0	50 mM Na ₂ H/KH ₂ phos 50 mM NaCl pH 7.0	50 mM Na ₂ H/KH ₂ phos 50 mM NaCl pH 7.5	50 mM Na ₂ H/KH ₂ phos 50 mM NaCl pH 8.0	50 mM CHES 50 mM NaCl pH 9.0
D	50 mM sodium acetate-acetic acid 200 mM NaCl pH 5.5	50 mM citrate-citric acid 200 mM NaCl pH 6.0	50 mM ADA 200 mM NaCl pH 6.5	50 mM sodium MOPS 200 mM NaCl pH 7.0	50 mM Na ₂ H/KH ₂ phos 200 mM NaCl pH 7.0	50 mM Na ₂ H/KH ₂ phos 200 mM NaCl pH 7.5	50 mM Na ₂ H/KH ₂ phos 200 mM NaCl pH 7.5	50 mM CHES 200 mM NaCl pH 9.0
E	300 mM NaCl pH 7.5	500 mM NaCl pH 7.5	50 mM Na ₂ H/KH ₂ phos 50 mM NaCl pH 7.5 + 10% glycerol	50 mM Na ₂ H/KH ₂ phos 200 mM NaCl pH 7.5 + 10% glycerol	50 mM NaCl pH 7.5 + 2 mM DTT	200 mM NaCl pH 7.5 + 2 mM DTT	Milli Q	H ₂ O (Tap)

* N-(2-acetamido)iminodiacetic Acid

Chapter 3

Phosphite Formulations

3.1 Assessment of Agrichemical Formulation

The results presented in this chapter were used to determine the EC₅₀ values for varying phosphite agrichemical formulations against *P. agathidicida* isolate 3770. The toxicity of all three commercial preparations of phosphite (Agri-Fos 600, Foschek and Phosgard), as well as the pure sodium phosphite salt, was assessed against the mycelial life stage of *P. agathidicida*. This adds to existing data on the direct toxicity of phosphite towards *P. agathidicida*^{19,93} but goes further, exploring the impact of other components of commercial phosphite formulations on *P. agathidicida* growth. The ability of a commercial adjuvant blend to increase the anti-oomycete effect of two plant-derived natural products was also assessed.

3.2 Agrichemical Formulations

The goal of the first experiment was to determine whether different commercial phosphite preparations had different inhibitory effects on *P. agathidicida*. While the concentration of phosphite could be standardised across agrichemicals, I aimed to discover whether the other components of each formulation affected activity.

EC₅₀ values were estimated by inoculating *P. agathidicida* onto plates containing various concentrations of each agrichemical. Pure sodium phosphite was used as a control. The relative area of the mycelial mat on each plate was estimated by squaring the mean radius (Methods 2.2.4). The concentration values were log-transformed, as other studies have done^{19,93}, and a normalised non-linear regression curve was generated for each data set (Figure 3.1). The EC₅₀ values for each agrichemical, estimated from this analysis, are summarised in Table 3.1.

ANOVA detected no significant difference in EC₅₀ between any of the agrichemicals (including pure phosphite). However, there was a clear visible difference in plate growth. *P. agathidicida* showed no growth when exposed to the commercial agrichemicals containing phosphite concentrations above 50 µg/mL. Pure phosphite

never completely inhibited growth. Some growth continued at 100 µg/mL and 200 µg/mL of phosphite alone.




Figure 3.1 Agrichemical inhibition graphs.

Each data point on the graph is an average of mycelial growth (n=4 independent biological replicates) in mm², error bars are SD from the measurements. The dotted lines indicate zero growth, and uninhibited growth in the absence of agrichemical (normal growth). Original concentrations before log transformations were µg/mL of phosphite.

Table 3.1 EC₅₀ values for inhibition of mycelial growth of *P. agathidicida* isolate 3770 with phosphite agrichemical formulations. Agri-Fos 600 , Foschek and Phosgard.

	EC ₅₀ (µg/mL)	R ²	85% confidence intervals (µg/mL)
Phosphite	0.90	0.85	
Agri-Fos 600	0.24	0.98	0.0004 to 0.64
Foschek	3.32	0.87	0.71 to 6.58
Phosgard	2.54	0.86	8.01 x10 ⁻⁵ to 5.77

I hypothesised that the three agrichemicals might cause complete inhibition because they were buffered to a different pH than pure sodium phosphite (which was unbuffered). However, when the pH was measured for each formulation, two (sodium phosphite and Agri-Fos 600) were basic (pH = 8.0) and two (Foschek and Phosgard) were acidic (pH = 5.9). Thus, it was unlikely the pH differences in the formulations were impacting the inhibition of *P. agathidicida*. There was so statistical difference between the EC₅₀ measurements. It is likely the pH plays a role elsewhere and future experiments with a pH variation will need to be carried out if it does play a role elsewhere.

3.3 Adjuvants and Surfactants

Following the phosphite comparison, the adjuvants, surfactants and stabilising agents (which comprise over 60% of the formulation⁹⁴) were assessed to determine their role in inhibition growth. Lonza provided their formulation for the adjuvants, surfactants and stabilising agents in Foschek under a confidentiality agreement. For simplicity, these other agents are referred to as adjuvants. The company also provided us with a pH-matched formulation of Foschek, minus the phosphite. This allowed a rigorous test of the contribution of adjuvants to growth inhibition. The non-

linear regression curves were generated, and have R^2 values > 0.95 for phosphite and the adjuvants (Figure 3.2). As expected, the adjuvants alone did not significantly inhibit growth of *P. agathidicida* isolate 3770, although mild inhibition was observed with the undiluted adjuvant (far in excess of anything that could be applied in planta). On the other hand, mixing adjuvants with phosphite replicated the effect seen with Foschek; that is, complete growth inhibition could be observed at high concentrations (Figure 3.2)




Figure 3.2 Inhibition of adjuvants, surfactants and stabilising agents. The same concentrations were used as in figure 3.1 for all chemicals. The combination of phosphite salt and adjuvants were a 1:1 ratio.

3.3.1 Natural Products and Adjuvants

Next, I tested whether the Lonza adjuvant mixture was able to improve the inhibitory effects of the plant-derived natural products, polygodial and falcarindiol. The EC_{50} values for these pure compounds were previously determined to be $0.64 \mu\text{g/mL}$ and $2.9 \mu\text{g/mL}$, respectively (S. Lawrence, unpublished data). Mycelial growth inhibition was determined for concentrations above and below these EC_{50} values: $0.1\text{-}1 \mu\text{g/mL}$ for polygodial and $1\text{-}5 \mu\text{g/mL}$ for falcarindiol. The results were compared to the

natural product used, without the commercial adjuvants. A stock of each natural product was mixed 1:1 (v/v) with the undiluted adjuvant formulation, and then this stock was diluted to the relevant working concentrations. The results of this experiment showed that the adjuvant mix had a dramatic effect on growth inhibition (Figure 3.3). Indeed, zero growth was observed at any tested concentration of either natural product, provided the adjuvants were present.




Figure 3.3 Natural products combined with the Lonza adjuvant mix. Each point shows the mean and standard deviation for biological triplicates. No growth was observed in the case of the natural products with adjuvants, so the error bars are zero. The x-axis plots the log₁₀ of natural product concentration in μg/mL.

3.4 Discussion

3.4.1 Quantifying Growth Inhibition

Currently, there is no standardised protocol for quantifying the growth and inhibition of *Phytophthora* mycelia. Previous research on *P. agathidicida* has used the distance grown outwards per day⁹³ or the optical density of the mycelial mat in solution⁹⁵,

although I found the latter protocol to be extremely variable in preliminary experiments (data not reported). For studying the inhibitory effects of bioactive compounds, Armstrong used “the radius of the mat, as a percentage of the radius of a mat growing in the absence of bioactive”¹⁹.

In this work, I focused on a “relative area” measurement, rather than a “relative radius”. Mycelial mats are not perfectly circular, so I measured the radius (from the agar plug to the edge of the mat) in six different locations of the mat. The average of these six measurements was then squared to yield a value that was proportional to the area of the entire mat. This method proved straightforward to implement, and accurately captured the relative mycelial growth that could easily be observed by eye.

3.4.2 Phosphite EC₅₀ Data

Agri-Fos 600 is the only phosphite formulation that has previously been used in studies of *P. agathidicida* growth inhibition. The EC₅₀ values reported in recent in vitro agar studies were 3.0 µg/ml and 4.0 µg/ml^{19,93} and 0.0 µg/ml from the optical density based method⁵⁴.

The data presented in this study contributes another layer to previous research, by testing whether specific formulations of phosphite alter EC₅₀. While differences in pH were observed between the different formulations, overall there was no statistically significant differences in EC₅₀ (Figure 3.1), and 95% confidence intervals were unable to be calculated. However, 85% confidence intervals (CI) are in Table 3.1. On the other hand, it is noteworthy that some mycelial growth was observed even at the highest tested concentrations of pure sodium phosphite (above 50 µg/mL), whereas the agrichemicals were able to prevent all growth at these elevated concentrations.

3.4.3 Using Adjuvants to Enhance the Bioactivity of Natural Products

The results comparing pure phosphite with formulated agrichemicals led me to hypothesise that adjuvants and surfactants may increase the potency of anti-oomycete agents other than phosphite. As shown in Figure 3.3, this was found to be the case for polygodial and falcarindiol. When they were mixed with the adjuvant blend used in Foschek, they displayed significantly enhanced efficacy. Indeed, it was not possible to determine EC_{50} values for the mixtures, as complete growth inhibition was observed at the lowest concentrations tested. Future work will involve testing much lower concentrations of each active ingredient.

3.4.4 Treatments for Kauri Dieback

Phosphite agrichemical formulations could be used to treat kauri dieback. A well-developed agrichemical with adjuvants and surfactants could be put forward for field trials.

Chapter 4

Investigating the Potential of Antimicrobial Resistance

This chapter focussed on the potential evolution of resistance in *P. agathidicida* isolates. The protocol reported by Miao (2016)⁵⁶ for evolving oxathiapiprolin resistance in *P. capsici* was adapted for use with polygodial, falcarindiol and pure sodium phosphite⁵⁶. The *P. agathidicida* isolate 3770 was serially passaged on media amended with increasing concentrations of each compound. Once no further growth was observed, the evolved isolates were assessed for changes in EC₅₀.

4.1 Results

4.1.1 Serial Passaging

The evolution experiment is outlined in Figure 4.1. Growth experiments were started on potato dextrose agar plates containing polygodial, falcarindiol or phosphite at a concentration equal to $0.25 \times \text{EC}_{50}$. This was done to start the long-term passaging experiments under conditions that permitted growth but may favour beneficial mutations. At the time the experiment was started, our best estimates for EC₅₀ values were 0.64 µg/mL for polygodial, 2.90 µg/mL for falcarindiol and 18.9 µg/mL for phosphite (although this was later shown to be an over-estimate; see Table 3.1). Therefore, the serial passages began with concentrations of 0.08, 0.36 and 2.3 µg/ml for the three compounds of interest.

The serial plating consisted of initially growing each inoculum in a set concentration and incubated for five days, or until the diameter of the mycelial mat reached 2/3 that of the agar (whichever came first). A second layer of agar (at the same concentration) is then poured over the established growth, and incubated further as previously described (Methods 2.2.5). At that point, plugs were taken and used to start the next round of evolution on agar amended with chemical at twice the concentration of the previous plate. Additional plugs were stored in water for further analysis. Serial passaging continued until chemical concentrations were reached that resulted in no growth for 20 days. This was up to a total of 7 passages (Figure 4.1), comprising up to five months of constant chemical exposure.




Figure 4.1 Flow diagram for evolving *P. agathidicida* for resistance towards polygodial, falcarindiol and phosphite.

Initial passages were performed on a single plate, until the EC₅₀ was reached. For plating at the EC₅₀ and beyond, three plugs were taken from each line and used to inoculate three independent plates. The fastest-growing clone(s) was used to inoculate three plates for the next round of evolution.

The extra 2 mm plugs were taken and stored in water were used later for assessing the parent isolate (3770) against its evolved strains.

4.1.2 Serial Passaging in the Presence of Polygodial

P. agathidicida grown in the presence of polygodial was the first to show a morphology change during the serial passaging process. This occurred at concentrations of 0.64 µg/mL (i.e. 1× EC₅₀) and beyond. The morphology changed from a regular, circular mat to random outcrops of mycelial growth. The appearance had irregular densities and a patchy texture (Figure 4.2), usually outside a period of regular mycelial growth. This change in morphology was seen frequently throughout the serial passages. The stored water plugs used to initiate further rounds of passaging were often taken from the mycelial area with this altered morphology.



Figure 4.2. Morphology changes in polygodial at original EC_{50} , $0.64\mu\text{g/mL}$.

This change in morphology was seen in a single round of evolution. Normal growth morphology is on the right, at $0.64\mu\text{g/mL}$. The change was seen when the second layer of agar (at $0.64\mu\text{g/mL}$) was poured over top and continued to grow (Left). These images were taken 5 days apart.

The growth rate was consistent during the early stages of the serial passage process. After plates with a new concentration of treatment were inoculated, there was often a period of normal growth. When the overlay was poured, there was a lag period of a few days before growth would resume at a steady rate. Higher concentrations of polygodial (above $2.5\mu\text{g/mL}$) eventually decreased the overall growth rate.

While there were notable changes in morphology and growth rate (at all polygodial concentrations), these did not translate into statistically significant differences in EC_{50} (Figure 4.3). Under the conditions of this experiment, the parental strain (*P. agathidicida* isolate 3770) showed $EC_{50} = 13.7\mu\text{g/mL}$ (95% CI 10.82 - 22.68 $\mu\text{g/mL}$). The evolved strain, isolated after 6 rounds of serial passaging, had an estimated $EC_{50} = 12.4\mu\text{g/mL}$, another wild type isolate that had no previous exposure to the chemicals (*P. agathidicida* isolate 3813) was also tested and had an $EC_{50} = 13.49\mu\text{g/mL}$. Overall, these data suggested that mutational processes had been occurring during the serial passaging, but they did not directly affect resistance

to polygodial. The 95% confidence intervals (95% CI) were unable to be calculated for the evolved isolate and isolate 3813 due to the concentration range measured.




Figure 4.3 Growth response curves for *P. agathidicida* 3770, the evolved isolate, and the *P. agathidicida* isolate 3813. All experimental data were fitted to the non-linear regression equation with $R^2 > 0.95$.

4.1.3 Serial Passaging in the Presence of Falcarindiol

P. agathidicida 3770 was also evolved by serial passaging in the presence of increasing falcarindiol concentrations. The growth in the presence of falcarindiol slowed significantly compared to the polygodial and phosphite evolutions during the serial passaging. The first inoculation layer at the start of each concentration increase was significantly reduced compared to the other evolutions (Phosphite and Polygodial). The growth normalised once the overlay of agar (Second layer) at the

same concentration that was placed on top the established growth. This growth pattern continued until the end of the serial plating when plugs were used to inoculate a plate at 23.2 $\mu\text{g}/\text{mL}$ (8x EC_{50}) and then growth was not seen for >20 days.




Figure 4.4. Morphology changes seen in Falcarindiol.

Normal growth of mycelial (Left) at 0.72 $\mu\text{g}/\text{mL}$ (0.25x EC_{50}) and the change in morphology, an uneven mycelial surface at 2.9 $\mu\text{g}/\text{mL}$ (Right). This change was seen after 15 days that included a the second layer of agar at 0.72 $\mu\text{g}/\text{mL}$, a complete concentration increase (1.44 $\mu\text{g}/\text{mL}$) and inoculation at another higher concentration of 2.9 $\mu\text{g}/\text{mL}$ (EC_{50}).

EC_{50} values were determined for the isolate from the last round of evolution and the two wild type isolates 3770 and 3813. As shown in Figure 4.5, effects on mycelial growth rate and EC_{50} were both marginal. The previously reported EC_{50} for *P. agathidicida* 3770 was 2.9 $\mu\text{g}/\text{mL}$ (S. Lawrence, unpublished data) and this study confirmed with this result, EC_{50} 3.0 $\mu\text{g}/\text{mL}$, (95% CI 2.5 to 3.6 $\mu\text{g}/\text{mL}$). Isolate 3813 was similar EC_{50} 3.3 $\mu\text{g}/\text{mL}$ (95% CI 3.0 to 3.8 $\mu\text{g}/\text{mL}$). If anything, the evolved isolate was slightly more sensitive in this assay EC_{50} 2.3 $\mu\text{g}/\text{mL}$ (95% CI 2.1 to 2.5 $\mu\text{g}/\text{mL}$) although none of the differences were significant when analysed in a one-way ANOVA using GraphPad prism 8.




Figure 4.5 Evolution of falcarindiol, *P. agathidicida* isolates vs an evolved isolate. Growth response curved from the *P. agathidicida* isolate 3770 parent, the evolved isolate, and a *P. agathidicida* isolate 3813. The EC₅₀ are 3.00 µg/mL, 2.3 µg/mL and 3.4 µg/mL respectively.

4.1.4 Serial Passaging in the Presence of Phosphite

Many factors led us to attempt the evolution of phosphite resistance. Some of these factors include recent studies showing that different isolates of the same *Phytophthora* species can be either sensitive or highly tolerant to phosphite⁵⁵ and that ever-increasing concentrations of phosphite-based agrichemicals are being required to maintain control of *Phytophthora* species in California’s citrus industry (implying the natural evolution of resistance)³⁴.

In keeping with the results of the other two evolution experiments, serial passaging in the presence of increasing sodium phosphite did not yield an isolate with a significant difference in EC₅₀. *P. agathidicida* isolate 3770 had a lower EC₅₀, 1.3 µg/mL

(95% CI 1.0 to 1.6 $\mu\text{g/mL}$) compared with isolate 3813, EC_{50} 2.2 $\mu\text{g/mL}$ (95% CI 1.8 to 2.4). The evolved strain was similar to its ancestor with an EC_{50} of 1.4 $\mu\text{g/mL}$ (95% CI 1.03 to 1.8 $\mu\text{g/mL}$)




Figure 4.6 Evolution of Phosphite, *P. agathidicida* isolates vs an Evolved isolate. Growth response curved from the *P. agathidicida* isolate 3770 parent, the evolved isolate, and a *P. agathidicida* isolate 3813. The EC_{50} measurements are 1.35 $\mu\text{g/mL}$, 1.4 $\mu\text{g/mL}$ and 2.15 $\mu\text{g/mL}$ respectively.

4.2 Discussion

4.2.1 Resistance Assessment

Other *Phytophthora* species have evolved resistance to traditional systemic fungicides in a relatively short period. Pyrimorph, zoxamide, and mandipropamid were all introduced during the early 2000's and already have well studied resistance mechanisms in *P. capsici*, *P. sojae*, *P. infestans* ^{22, 47, 49, 50, 52, 96}. Here, we were unable

to establish whether resistance to polygodial, falcarindiol or phosphite treatments evolved in *P. agathidicida*.

Unexpectedly, all three chemicals did not show an increase in EC₅₀ from the ancestor (Isolate 3770) and the evolved strains. The inclusion of isolate 3813 was initially as a sensitive isolate compared to Isolate 3770 and the directed evolution isolates.

However, isolate 3813 was more resistant than expected. Isolate 3813 continued to be included to address geographical isolate variability and sensitivity⁵⁵, and an extra standard for comparison.

The protocols I adapted from Miao (2016)⁵⁶ was carried out for shorter periods of time than the original experiments. The original protocol slowly evolved *P. capsici* in 15-20 day cycles, and until the growth rates for the isolates were the same as normal growth on potato dextrose agar. Further adaptations of the protocol for *P. agathidicida* could include a longer period of exposure to the chemical and smaller incremental increases in concentration. The changes in phenotype seen in response to polygodial and falcarindiol indicate that some intracellular changes are occurring, even though these were not reflected in EC₅₀. This could be due to cytotoxicity of the compounds or mutations. Sequencing the genomes of the parental and evolved isolates would be necessary to confirm any mutations due to these chemicals.

4.2.2 Solvent Used to Dissolve Natural Products

One unexpected finding from my experiments was the high EC₅₀ values for polygodial (Figure 4.5). The serial passaging experiment was designed based on the EC₅₀ value determined by our collaborator, Dr Scott Lawrence (University of Otago). He reported an EC₅₀ of 0.68 µg/mL for *P. agathidicida* 3770, while I obtained a value of 13.7 µg/mL. A potential reason for this may be due to the solvents used in the experiments. S. Lawrence used an alcohol extract while I used DMSO dissolved solution. The highest concentration tested using the alcohol extracted polygodial was 10 µg/mL, while our polygodial DMSO solution concentration went up to 50 µg/mL. The solvent in which polygodial is dissolved may impact the growth of *P. agathidicida*.

The actual EC₅₀ for our experiment is likely the EC₅₀ of between 13.7 and 13.49 µg/mL, as determined by isolate 3770, and isolate 3813. Under these conditions there may not have been enough of a selection pressure. More experiments are required to determine the effect the solvent has on *P. agathidicida* and further concentration ranges measured.

4.2.3 Long Term Implications for Kauri Dieback.

The evolved EC₅₀ measurements did not differ significantly to the geographical isolate 3813 in our forced evolution. This indicates that it is likely *P. agathidicida* does not evolve resistance quickly. While this was the first attempt at forced evolution, it should be an avenue that continues to be explored and assessed for all potential treatments of kauri dieback. This gives hope for a long term response for kauri dieback.

Chapter 5

Protein Characterisation

This section of research focuses on the *P. agathidicida* PaORP1 gene and the expression of the Oxysterol binding domain (ORD) of the PaORP1 protein. ORP1 was identified as the gene target for oxathiapiprolin. Oxathiapiprolin was developed as a specific anti-oomycete compound and has a known resistance mutation in *P. capsici*⁵⁶. A single point mutation resulting in a glycine to tryptophan substitution in the PcORP1 protein.

The PaORP1 gene produces oxysterol binding proteins that traffic sterols and oxysterols throughout the cell. The structure and function of OSBPs are limited to the general mechanism, i.e. golgi to endoplasmic reticulum transport. Furthermore, humans and yeast have been the only organisms extensively researched for structure and function of OSBP thus far.

The PaORP1 gene was identified, amplified, annotated, and assessed for genetic diversity. Wild type and mutant (glycine 771 to tryptophan, G771W) ORD domains from PaORP1 were commercially synthesised, then expressed in *E. coli* and purified.

5.1 Results

5.1.1 Bioinformatics

The *P. capsici*, *P. infestans*, and *P. sojae* *ORP1* sequences were obtained from Andreassi, Gutteridge, Pember, Sweigard and Rehberg⁹⁰. These were aligned to an unannotated draft genome of *P. agathidicida* isolate 3772⁸⁶. This analysis identified a *P. agathidicida* gene with high sequence identity to these known *ORP1* genes. In particular, the candidate *PaORP1* was 73% identical to the *P. capsici* gene sequence, 69% identical to the *P. infestans* gene sequence, and 67% identical to the *P. sojae* sequence. The *PaORP1* gene is 3323 base pairs (bp).

Kamoun¹¹ identified key molecular genetic features of oomycete genomes. The transcriptional start site for *PaORP1* is predicted to be 216 bp upstream of the start codon. Kamoun¹¹ identified consensus splice sites for introns (5' GTRNGT... YAG 3') and *PaORP1* has one set of these sequences, suggesting that it possesses one

intron. The upstream splice site (5' GTACT 3') is located 328 nucleotides from the transcriptional start site, while the 3' splice site is 90 bp downstream. The position and relative size of the intron are shown in Figure 5.1.




Figure 5.1. *PaORP1* gene and protein annotation.

The gene was annotated based on the information provided Kamoun ¹¹. The translated polypeptide contains the typical domains found within the longer oxysterol binding proteins, as well as oxysterol binding protein-related proteins.

When the intron is spliced out, it removes two unfavourable stop codons in the predicted protein sequence. The protein produced from this gene contains 961 amino acids.

5.1.2 Gene Sequencing

To assess possible sequence diversity at the *PaORP1* locus, genomic DNA was prepared from five geographically distinct isolates of *P. agathidicida* (Materials Table 2.1). In spite of a standardized protocol (Methods 2.2.6 - 2.2.9) total yields of genomic DNA were variable, ranging from 850 ng to 20,800 ng of DNA from 40 mg of mycelial mat tissue.

The *PaORP1* gene was amplified from the genomic DNA preparations. As the gene length was quite long (3379 bp), four different forward primers were designed for use in amplification and subsequent sequencing. Despite many attempts to optimise the

reaction conditions, amplification of the full-length gene was not achieved using the primers OSBP_For1 and OSBP_Rev. On the other hand, primers OSBP_For2, OSBP_For3 and OSBP_For4 all worked with OSBP_Rev, albeit with variable yields of the product

There are several mutations in the *P. capsici* *ORP1* gene (pcORP1) that are known to give resistance to oxathiapiprolin⁵⁸. These mutations are all found in an area of 200 amino acids, from position 700 to 900, which is located in the oxysterol binding domain (ORD) (Figure 5.1) Fortunately, the DNA encoding this region is contained within the PCR product resulting from amplification with OSBP_For4 and OSBP_Rev.

Sequencing with OSBP_For4 revealed that *PaORP1* was almost identical to the pcORP1 gene in the resistance-causing positions. The only differences were that Thr768 in pcORP1 was a serine in *PaORP1* and Phe877 was replaced by histidine.

The sequencing data also showed that all five *P. agathidicida* isolates had identical sequences in this region of the *PaORP1* gene. None contained any of the known oxathiapiprolin resistance mutations. For example, the G769W mutation is known to confer resistance in *P. capsici*⁵⁶. The equivalent residue in PaORP1 is G771, which was conserved as glycine in all five sequenced isolate (Materials Table 2.3).

5.1.3 Gene Synthesis and Protein Modelling

The online prediction tools SWISS-MODEL⁹¹ and CDART⁹⁷ were used to predict the boundaries of the conserved protein domains and a protein structure. The structure of the ORD from the *Saccharomyces cerevisiae* OSBP homologue (Osh), Kes1/Osh4, had been determined previously by others⁶⁶. This aided in the definition of the PaORP1 ORD, located from amino acids 620 to 940. The homology model generated by SWISS-MODEL suggested that the N-terminus begins almost immediately as an alpha helix, before becoming the characteristic almost beta-barrel and cap formation previously defined by Im, Raychaudhuri, Prinz and Hurley⁶⁶ (Figure 5.2).




Figure 5.2. Structures of ORDs for PaORP1 and KES1/Osh4. Predicted structure of PaORP1 (Red) from SWISS-MODEL⁹¹ next to the known structure of the KES1 ORD (Green).

The DNA sequence encoding the ORD was optimized for expression in *E. coli*, synthesized, and cloned into the expression vector pET28a by Twist Bioscience (San Francisco, CA, USA). The cloned insert also encoded an N-terminal His₆ tag, followed by a cleavage site for the tobacco etch virus (TEV) protease. A gene encoding the G771W mutation, predicted to impart oxathiapiprolin resistance, was also synthesized and cloned by Twist Bioscience.

5.1.4 Confirmation of Plasmid Insert.

A restriction enzyme digest was performed to confirm the size of the PaORP1 insert in the pet28a plasmid. Twist Bioscience had cloned the insert as an NcoI/XhoI fragment, while a KpnI site was located inside the PaORP1 gene. Digestions with combinations of these enzymes showed the expected banding patterns (Figure 5.3). For example, the KpnI-XhoI digest shows a 944 bp fragment of the paORP1 insert, and the remaining 5286 bp fragment of the pet28a vector. The NcoI-XhoI digest that also confirms the presence of the inserted sequence for both the wild type and mutant.




Figure 5.3. Enzyme Digest of PaORP1 pet28a plasmid.

Results of a KpnI - XhoI, and NcoI- XhoI digest for both PaORP1 pet28a plasmids.

Columns 2-4 are Wild type plasmid, and 5-7 are the Mutant G771W plasmid.

5.1.5 Initial Protein Expression and Purification.

E. coli strain BL21 Gold was used for initial expression trials of PaORP1 wild type and PaORP1 mutant (G771W) (Materials 2.1.3 and 2.1.4). Interestingly, after overnight induction, the following morning yielded two very different cultures. The culture expressing PaORP1 mutant (G771W) was saturated, whereas the culture expressing PaORP1 wild type had not appeared to increase in optical density after protein expression was induced.

As expected, based on the culture observations, SDS-PAGE gel electrophoresis showed that PaORP1 wild type had not been expressed. However this was due to human error and was addressed in a follow up experiment. On the other hand,

PaORP1 (G771W) was expressed initially and was able to be purified using metal affinity chromatography.




Figure 5.4. Initial expression and purification trials of PaORP1 proteins (Wild type and Mutant).

The uninduced sample was taken before IPTG was added to the broth. The induced sample was taken after the overnight incubation. The soluble cell lysate and insoluble samples were taken for comparison after the cells were lysed by sonication. A Column flow through sample was taken to ensure that our PaORP1 sample bound to the column. For the mutant protein, the elution fraction showing the highest A280 absorbance peak was also analysed. Fraction 16 gives an indication of all the proteins that bind to the his-trap column, while elution fraction 21 contains PaORP1 (~37kDA).

5.1.6 Optimisation of Purification

After the initial expression and purification trials, an extensive series of optimisation experiments were undertaken. All changes made to the purification methodology are applicable to both the wild type and mutant PaORP1, and various experiments were conducted with each protein. Therefore, in this section of results, they will not be distinguished.

The first changes were the addition of 10% glycerol and 5 mM β -mercaptoethanol to all the purification buffers (i.e. lysis, wash and elution buffers). The lysis method was also changed from sonication to French-press. The additional components of the lysis buffer increased the soluble protein abundance from < 0.3 mg to 0.68 mg while French-press increased the yield of soluble protein to 1.56 mg to 2.5 mg.

Terrific broth (TB) and IPTG were also switched to an autoinduction medium. In part, the switch was to help control bacterial pellet size. Overnight growth in TB produced up to 30 g of bacterial pellet per litre. Autoinduction medium cut this down significantly to 15-20 g, which made it easier to resuspend in the 30 mL volume required to use the French-press.

Another change to the protein purification method was the addition of the detergent, Tween-80, to the lysis buffer only. This also increased the yield of soluble protein to 4.5 mg to 6.5 mg. The effect of each change in the protocol is summarised in Figure 5.6. In addition, exchange from elution buffer (containing high concentrations of imidazole) to storage buffer was attempted using both centrifugal diafiltration and dialysis. The latter method was found to minimise aggregation and precipitation of the purified protein.




Figure 5.5. Changes in protein abundance associated with the optimisation of the protocol.

A comparison of protein abundance compared to the initial expression (set to a relative abundance of 1). Listed here are step in the purification where a significant increase in protein abundance was observed.

In the initial test (Results 5.1.5), most expressed PaORP1 protein was in the insoluble fraction. The incremental changes to the protocol shifted the ratio towards more soluble protein, although the majority remained in the insoluble fraction (Figure 5.6).




Figure 5.6. Optimized expression and purification of PaORP1 (Wild type and Mutant). This SDS-PAGE gel contains the re-expression of PaOR1 after some optimization with PaORP1 mutant. A high abundance of PaORP1 is present in the insoluble fraction. Purifying the mutant has increased abundance due to the changes listed in this section. Elution fractions 8 and 9 are the elution of protein that non-specific bind to the hi-trap column. While elution fractions 8 to 12 contain the mutant PaORP1.

5.1.7 Fluorescence Thermal Shift assay

Initial quantitative tests showed that PaORP1 was prone to aggregate on storage. A preliminary screen suggested that it was most stable in sodium acetate buffer at pH 5.0 (Methods 2.2.19). A fluorescence thermal shift (FTS) assay was used to validate this result and to determine the unfolding temperature of PaORP1 in a variety of different buffers (Table 5.1).

	1	2	3	4	5	6	7	8
A	37.8 °C	36.3 °C	36.8 °C	37.3 °C	34.8 °C	33.8 °C	33.3 °C	34.8 °C
B	35.3 °C	33.3 °C	34.3 °C	36.3 °C	33.8 °C	32.8 °C	32.8 °C	29.8 °C
C	34.3 °C	33.3 °C	29.3 °C	23.4 °C	32.3 °C	34.3 °C	30.3 °C	34.8 °C
D	34.3 °C	32.3 °C	34.3 °C	30.8 °C	31.8 °C	31.8 °C	33.8 °C	33.3v
E		35.8 °C	25.9 °C			32.8 °C	25.4 °C	

Table 5.1 FTS assay to measure stability in different buffer solutions.

The results show the maximum temperature the PaORP1 protein is stable at. The higher the temperature, the more stable the PaORP1 protein in solution. Buffers can be found in Methods 2.2.19.

The results in Table 5.1 (above) confirmed that the most stable buffer is still sodium acetate pH 5.0 (well A1 in Table 5.1). A comparable condition was in A4, which was imidazole pH 7.0 and 150 mM sodium chloride. These are already components of the lysis and elution buffers.

5.1.8 Size Exclusion Chromatography

To determine the apparent oligomeric states of the two PaORP1 proteins fragments, they were passed down a Superdex 200 Increase 10/300 GL size exclusion column (Methods 2.2.18). Three standards were also run: conalbumin, albumin and dextran blue, where their molecular weights are 75 kDa, 40 kDa, 2000 kDa respectively. Albumin is about the same size as the PaORP1 monomer (37 kDa), while conalbumin is about the same size as a PaORP1 dimer (74 kDa). Dextran blue was used to determine the void volume of the column. The results are shown in Figure 5.7.




Figure 5.7. Size Exclusion Chromatography of PaORP1 variants: wild type (left) and G771W mutant (right).

The proteins used as standards are conalbumin (75 kDa) and albumin (40 kDa), the two peaks seen in yellow. Along with a Dextran Blue standard, separate pink line.

If the expressed ORD of PaORP1 was a monomer, then it should appear around the 40 kDa albumin standard, as the PaORP1 ORD is 37 kDa. If expressed ORD of the PaORP1 protein formed a dimer, then it would appear in a similar position to conalbumin around 75 kDa. Higher molecular weight forms would elute at lower volumes (nearer the dextran blue peak). The PaORP1_wt (wild type) appeared to elute as a mixture of dimer and monomer (elution volumes of ~11.5 mL and 15.0 mL respectively in Figure 5.7), while the G771W mutant was mostly dimeric. In both cases, higher-order oligomers (elution volumes less than 11.5 mL) were also apparent.

5.2 Discussion

5.2.1 Protocol Development

The changes in expression and purification protocols were made over several months (Methods 2.2.17.2).

The initial expression protocol involved growth at 37 °C for a few hours, then the addition of IPTG and continued incubation at 18 °C for 16 to 18 hrs (overnight). The change to autoinduction medium allowed for a gentle transition into PaORP1 transcription. However, it greatly affected the bacterial pellet weight. Before this change, the bacterial pellet could weight more than 30 g. It was difficult to resuspend, so it was usually divided into multiple aliquots to be purified separately. The change to auto-induction medium reduced the pellet size considerably and enabled easier resuspension. In turn, this also led to a decrease in the viscosity of the solution that underwent lysis using the French-press.

Ultimately, an isocratic method was used to purify PaORP1 (Methods 2.2.17.2). The best yields were obtained when the nickel affinity column was washed at a constant imidazole concentration of 150 mM, before stepping up to elute at 240 mM. After all of these changes and the development of the protocol, the expected yield of PaORP1 from a 5-10 g bacterial pellet after purification, dialysis, and concentrating would be 7.5 mg to 10 mg.

5.2.2 PaORP1 Purity, Stability and Oligomeric State.

This was the first study to attempt biophysical characterisation of any *P. agathidicida* protein. The optimised protocol yielded PaORP1 protein that was at least 90% pure (Figure 5.5) and was sufficiently concentrated to assess stability and oligomeric state. The FTS assays showed that PaORP1 is not particularly thermostable in vitro, with unfolding temperatures from 25-38 °C (depending on the storage buffer). At the same time, it is known that the optimum growth temperature of *P. agathidicida* is 21.5 °C and the maximum temperature at which it can grow is 25 °C⁵. Therefore, it is

perhaps not surprising that proteins from this organism unfold at the temperatures we observed for PaORP1.

OSBPs are capable of dimerization but whether in hetero or homo dimer state remains unknown⁹⁸. A monomer was observed in the crystal structure of the yeast KES1/Osh4 homologue. However, homodimers have been observed with native OSBP⁹⁹. My size exclusion chromatography results (Figure 5.7) show that PaORP1 is able to dimerise as well, although it may exist in a concentration-dependent monomer-dimer equilibrium.

5.2.3 Next Steps

5.2.3.1 Affinity of PaORP1 For Oxathiapiprolin

Oxathiapiprolin is a highly potent anti-oomycete compound, but currently there is no published data on the strength of its interaction with its protein target, ORP1. This will be able to be assessed now that a protocol for obtaining PaORP1 has been optimised. Determining the binding affinity could be done through isothermal titration calorimetry (ITC). A potential limitation of using ITC to assess the binding affinity could be that very low concentrations of oxathiapiprolin are likely to be necessary^{19, 48, 57}, which may make it difficult to detect the interaction. In contrast, I predict that the mechanism of resistance conferred by the G771W mutation is to weaken the interaction between the agrichemical and its target. Future experiments will now be able to test this hypothesis.

5.2.3.2 Structure and Function

Now that the protocol to obtain stable, usable protein has been established we may be able to obtain crystal structures.

No crystal structure has been recorded yet of any *Phytophthora* ORP1 protein. However, there are crystal structures of Kes1/Osh4 oxysterol binding domain^{63, 64, 66} from *Saccharomyces cerevisiae*. The studies on Kes1/Osh4 showed it is capable of binding both sterols and oxysterols. However, to obtain the empty binding site, the 29

amino acid N-terminal lid was removed. The lid structure is believed to stabilise binding within the active site and suggests it is a flexible component to the ORD^{63, 64}

The crystal structure of PaORP1 domain will most likely have a sterol or oxysterol within the active site. Im (2005)⁶⁶ reported they were unable to obtain a crystal structure with an empty binding site with the full ORD domain, including the lid structure. Obtaining the crystal structure for PaORP1 variants produced from the protocol in this study could yield insight into the specific function of PaORP1 in *Phytophthora*. In particular, obtaining a structure with a bound ligand may give a clue to the physiological role.

Overall, the work described in this chapter represented the first attempt to characterise any *P. agathidicida* protein in vitro. While it demonstrated some of the challenges of working with proteins from this organism, it also set the groundwork for future studies.

Chapter 6

Discussion

6.1 Research Overview

The overarching goal of this research was to investigate the sensitivity and resistance of *P. agathidicida* to various anti-oomycete compounds. Progress toward this goal was achieved. In particular, this thesis is the first to report on:

- A comparison of different phosphite agrichemical formulations for efficacy against *P. agathidicida*;
- Formulations that may enhance the efficacy of plant-derived natural products;
- The relative ease (or lack thereof) of *P. agathidicida* evolving resistance to bioactive compounds; and
- The expression and purification of a known drug target from *P. agathidicida*.

6.2 Phosphite Treatment Viability

Phosphite is considered as a short-term option for the treatment of kauri dieback. Phosphite formulations are not curative. Both spray and injection treatments require a rigorous surveillance programme and periodic retreatment ¹⁰⁰.

Thus far, the treatment of *P. agathidicida* has been limited to one phosphite formulation. The first phosphite study in *P. agathidicida* was published in 2013 ⁹³ and forestry trials began in 2015 ¹⁰⁰⁻¹⁰³. This work used the Agri-Fos 600 phosphite formulation. These field trials used a girth measurement, and injection sites every 20 cm or 40 cm. The injected kauri presented with leaf yellowing, a sign of phytotoxicity, and then required monitoring for three years post-injection. The levels of phosphite in the roots also were measured after 6 months, concluding that the concentration in the roots was less than 0.4 µg/mL ¹⁰¹⁻¹⁰³.

To date, the only other comparison of two phosphite formulations, Agri-Fos 600 and Foschek, was carried out to assess the effects of different wetting agents and adjuvants alone using cabbage leaf. This was a preliminary study before assessing the uptake and maintenance of phosphite levels in *Pinus radiatus* for an unspecified

disease. However Foschek was recommended to proceed to field trials due to stability of the adjuvants and surfactants.

In Chapter 3, I rigorously compared three commercial phosphite preparations with the pure active ingredient. Overall all three of the commercial phosphite preparations inhibit the growth of *P. agathidicida*.

As described in Chapter 3.2, there was no significant difference between Agri-Fos 600 and the other commercial formulations, Foschek and Phosgard. Therefore, these should also be considered for the treatment of kauri dieback disease. One caveat is that my research was performed entirely in vitro. In planta trials are also required to optimise bioavailability and reduce phytotoxic side effects.

6.3 Natural Products and a Basis for Agrichemical Development

Building on the results with phosphite, this study was the first to test whether the plant-derived bioactives polygodial and falcarindiol would be more effective against *P. agathidicida* if they were combined with a commercial adjuvant mix. As shown in Chapter 3 (Figure 3.3), there is sufficient evidence warrant follow up experiments to determine the weather these natural products could be developed into agrichemical formulations for the treatment of kauri dieback.

The formulation of an agrichemical can take years of development¹⁰⁴. The non-bioactive ingredients play an important role in stabilising the chemicals in solution, plant application, and uptake and retention in the plant³⁰. Thus, the complexity of different formulations and active ingredients can play an important role in the inhibition of the target organisms. One thing to note is that *Phytophthora* species and higher plants have a similar chemical makeup of their cell walls^{13, 15, 17}, meaning that there is the potential to formulate an agrichemical so that it is optimised for in planta bioavailability and increased anti-oomycete action at the same time.

Because of time constraints, only limited concentration ranges and ratios of natural product to adjuvant were explored in Chapter 3.2.2. Nevertheless, these promising results justify further studies to determine the most effective ratios of the different components. These studies would aid the development of the scaling process, if an agrichemical was to be developed.

Interestingly, both polygodial and falcarindiol have been tested as antibiotics and anti-cancer agents in humans. In both cases, the natural products are synergistic with other treatments^{74, 75, 105-108}. Another avenue of future work will be to explore whether these compounds synergise with other known anti-oomycete compounds, which in turn would be beneficial for agrichemical development.

6.4 International Standards for Risk of Resistance

International awareness around antimicrobial resistance has increased exponentially over the last two decades. This is not just related to multidrug resistance human pathogens and hospital-acquired infections. Pesticides, fungicides, and other agrichemicals have also been assessed for their mode of action and risk assessments are now often undertaken for the likelihood of resistance development.

Four of the most recently developed anti-oomycete and conventional fungicides have undergone resistance assessments. Larger countries, such as China and Korea, are now requiring risk assessments before an agrichemical can be commercially available. The new treatments for *Phytophthora* include oxathiapiprolin, zoxamide, mandipropamid, and pyrimorph. All these treatments have a known mode of action and a known path to resistance, in part, due to these new requirements.

Zoxamide is a β -tubulin inhibitor that inhibits true fungi and oomycetes. It is a competitive inhibitor of β -tubulin; it competes with colchicine binding at cystine 239 of the β -tubulin protein. Zoxamide resistance is associated with a C239S mutation⁴⁷.

Mandipropamid targets oomycetes by inhibiting cell wall synthesis. Mutations in the cellulose synthase-like A3 (CesA3) protein are associated with mandipropamid

resistance. A significant concern with mandipropamid resistance is cross-resistance to other carboxylic acid amides (CAA) fungicides. Pyrimorph is also known to target the CesA3 protein ^{51, 52, 84}.

Oxathiapiprolin specifically inhibits *Phytophthora* by targeting the ORP1 proteins, and there are numerous mutations in the ORD associated with oxathiapiprolin resistance. This study looked at the first reported resistance-associated change in ORP1; a glycine to tryptophan point mutation first described in *P. capsici* ⁵⁶⁻⁵⁹. *P. agathidicida* isolates do not have the mutation associated with resistance, and there is no genetic diversity within the *P. agathidicida* isolates ORP1 ORD (Chapter 5.1.2 and 5.1.3).

Typically, new treatments focus on the well-studied *P. infestans*, *P. sojae* or *P. capsici*. However, the mode of action of these agents is applicable to *P. agathidicida*. This type of pre-screening for resistant isolates led to an insight into the PaORP1 gene and sensitivity of all *P. agathidicida* isolates. The known mechanisms allow us to take a genetic approach to pre-screen a treatment and allows for an added level of knowledge for an informed decision for the treatment of kauri dieback.

6.5 Attempted Evolution of Resistance

This research was the first to attempt the directed evolution of *P. agathidicida* towards greater antimicrobial resistance. The methodology was based on one described elsewhere ⁵⁶ and attempted to force evolution by serial passaging on amended media (Chapter 4.1).

The development of phosphite tolerance in many *Phytophthora* species, such as *P. infestans*, *P. sojae*, *P. capsici*, is due to the extended exposure to phosphite agrichemical treatments. Phosphite has also been used to treat *P. agathidicida* in the field ^{93, 100, 101, 103}. While *P. agathidicida* currently shows susceptibility to phosphite, it may also develop tolerance over time.

The natural products used in this research are a new addition to the anti-*Phytophthora* arsenal of tools. Both have unique modes of action and have been studied for treating a multitude of microbes, cancer, and other human diseases. Polygodial affects the electrochemical gradient across membranes and falcarindiol causes cell cycle arrest^{72, 82}. On the other hand, phosphite is thought to have a broad range of anti-oomycete effects, based on its incorporation into cellular processes instead of phosphate, affecting an extensive range of metabolic and structural components in *Phytophthora*.

Despite serial passaging for several months, I was unable to increase the resistance of *P. agathidicida* towards polygodial, falcarindiol or phosphite. I did, however, see morphological changes in the mycelia growing in the presence of the anti-oomycete compounds (e.g. Figure 4.2 and Figure 4.4). One reason could be the complex modes of action for all three chemicals. It is likely that resistance to each compound will require more than one, and perhaps many, mutational events. This is in contrast to oxathiapiprolin, where single mutations in PaORP1 (such as G771W) confer resistance.

If multiple mutations are required to give resistance to polygodial, falcarindiol or phosphite then this bodes well for using these compounds in the field. Further directed evolution with elevated mutation rates (e.g. through the addition of chemical mutagens) will be required to explore the resistance to these compounds further.

6.6 Expression and Purification of *P. Agathidicida* Proteins

Chapter 5 described the successful expression and purification of the recombinant ORD domain of PaORP1. Previous studies on oxysterol binding proteins have focused on the yeast and human proteins^{60-66, 98, 99, 109-120}. Human OSBP genes have been expressed successfully in *E. coli*^{66, 98} while the yeast proteins have been functionally characterised using gene knockout and RNA knockdown experiments^{61,}

^{63, 65, 66}

There are no previous reports in the literature of recombinantly expressing *P. agathidicida* proteins. Armstrong (2018)¹⁹ attempted to express the intracellular domain of a G-protein coupled receptor in *E. coli* but was unable to gain any soluble protein¹⁹. The results described in this thesis suggest that *E. coli* may not be the ideal host for expressing *P. agathidicida* proteins, but that this can be achieved with careful optimisation.

With an optimised purification protocol in place for PaORP1, it will now be possible to study its interaction with oxathiapiprolin. Further into the future, proteins with other resistance-associated mutations (Discussion 6.4 above) could also be expressed and purified to determine the biochemical basis of resistance and sensitivity.

6.7 Conclusion

The research presented in this thesis addresses some concerns for the community fighting hard to save kauri from *P. agathidicida*; such as limited treatment options and the potential for resistance to develop. Various aspects of four potential treatments (phosphite, polygodial, falcarindiol and oxathiapiprolin) have been studied. Perhaps most promisingly, I have shown the potential to formulate potent agrichemicals by adding adjuvants to the natural products polygodial and falcarindiol. While there is an urgent need for considerably more research, the results presented in this thesis suggest that new treatment options for kauri dieback are achievable.

References

1. King, M. *Ngā iwi o te motu: 1000 years of Māori history*, Edn. Rev. ed. (Reed Books, Auckland, N.Z; 2001).
2. Cassie, V.D. New Zealand Conifers. *Journal of the Arnold Arboretum* **35**, 268-273 (1954).
3. Ecroyd, C.E. Biological flora of New Zealand 8. *Agathis australis* (D. Don) Lindl. (Araucariaceae) Kauri. *New Zealand Journal of Botany* **20**, 17-36 (1982).
4. Wyse, S.V., Burns, B.R. & Wright, S.D. Distinctive vegetation communities are associated with the long-lived conifer *Agathis australis* (New Zealand kauri, *Araucariaceae*) in New Zealand rainforests. *Austral Ecology* **39**, 388-400 (2014).
5. Weir, B.S. *et al.* A taxonomic revision of *Phytophthora* clade 5 including two new species, *Phytophthora agathidicida* and *P. cocois*. *Phytotaxa* **205**, 21-38 (2015).
6. Beever, R.E., Waipara, N.W., Ramsfield, T.D., Dick, M.A. & Horner, I.J. Kauri (*Agathis australis*) under threat from *Phytophthora*. *Phytophthoras in forests and natural ecosystems* **74**, 74-85 (2009).
7. Hill, L., Waipara, N., Stanley, R. & Hammon, C. Kauri Dieback Report 2017: An investigation into the distribution of kauri dieback, and implications for its future management, within the Waitakere Ranges Regional Park. *Kauri Dieback Report* **2**, 1-40 (2017).
8. Marshall, D. in Environment, Climate Change and Natural Heritage Committee (New Zealand Government; 2014).
9. Kamoun, S. Plant pathogens: Oomycetes (water mold). *Protists*, 689-695 (2009).
10. Kamoun, S. *et al.* The top 10 oomycete pathogens in molecular plant pathology. *Mol Plant Pathol* **16**, 413-434 (2015).
11. Kamoun, S. Molecular genetics of pathogenic oomycetes. *Eukaryotic Cell* **2**, 191-199 (2003).
12. Judelson, H.S. & Blanco, F.A. The spores of *phytophthora*: Weapons of the plant destroyer. *Nat Rev Microbiol* **3**, 47-58 (2005).
13. Tokunaga, J. & Bartnicki-Garcia, S. Structure and differentiation of the cell wall of *Phytophthora palmivora*: cysts, hyphae and sporangia. *Archiv Fur Mikrobiologie* **79**, 293-310 (1971).
14. Gaulin, E. *et al.* Cellulose binding domains of a *phytophthora* cell wall protein are novel pathogen-associated molecular patterns. *Plant Cell* **18**, 1766-1777 (2006).
15. Lippman, E., Erwin, D.C. & Bartnicki-Garcia, S. Isolation and chemical composition of oospore-oogonium walls of *Phytophthora megasperma* var. *sojae*. *Journal of General Microbiology* **80**, 131-141 (1974).

16. Lawrence, S.A., Armstrong, C.B., Patrick, W.M. & Gerth, M.L. High-throughput chemical screening identifies compounds that inhibit different stages of the *Phytophthora agathidicida* and *Phytophthora cinnamomi* life cycles. *Frontiers in Microbiology* **8** (2017).
17. Bartnicki-Garcia, S. Chemistry of hyphal walls of *Phytophthora palmivora*: sporangia and oospore. *Microbiology* **42**, 57-69 (1966).
18. Hardham, A.R. The cell biology behind *phytophthora* pathogenicity. *Australasian Plant Pathology* **30**, 91-98 (2001).
19. Armstrong, C. in Faculty of Science, Vol. Masters of Science 122 (University of Otago, 2018).
20. Hardham, A.R. Cell biology of plant-oomycete interactions. *Cell Microbiol* **9**, 31-39 (2007).
21. Tsao, P.H. in *Phytophthora diseases of citrus and other crops in the Mediterranean area*, Vol. 20 11-17 (EPPO Bulletin, 1990).
22. Hermansen, A., Hannukkala, A., Nærstad, R.H. & Brurberg, M.B. Variation in populations of *Phytophthora infestans* in Finland and Norway: mating type, metalaxyl resistance and virulence phenotype. *Plant Pathology* **49**, 11-22 (2000).
23. Pasteris, R.J. *et al.* Discovery of oxathiapiprolin, a new oomycete fungicide that targets an oxysterol binding protein. *Bioorgan Med Chem* **24**, 354-361 (2016).
24. Royal, T.A.C. Politics and knowledge: Kaupapa Maori and matauranga Maori. *New Zealand Journal of Educational Studies* **47**, 30 (2012).
25. Hikuroa, D. Mātauranga Māori-the ūkaipō of knowledge in New Zealand. *J Roy Soc New Zeal* **47**, 5-10 (2017).
26. Morton, V. & Staub, T. A short history of fungicides. *American Phytopathological Society* **10**, 2008-0308 (2008).
27. Achary, V.M.M. *et al.* Phosphite: a novel P fertilizer for weed management and pathogen control. *Plant Biotechnology Journal* **15**, 1493-1508 (2017).
28. Dobrowolski, M.P., Shearer, B.L., Colquhoun, I.J., O'Brien, P.A. & Hardy, G.E.S. Selection for decreased sensitivity to phosphite in *Phytophthora cinnamomi* with prolonged use of fungicide. *Plant Pathology* **57**, 928-936 (2008).
29. Eshraghi, L. *et al.* Defence signalling pathways involved in plant resistance and phosphite-mediated control of *Phytophthora cinnamomi*. *Plant Molecular Biology Reporter* **32**, 342-356 (2013).
30. Hardy, G., Barrett, S. & Shearer, B.L. The future of phosphite as a fungicide to control the soilborne plant pathogen *Phytophthora cinnamomi* in natural ecosystems. *Australas Plant Path* **30**, 133-139 (2001).
31. Gómez-Merino, F.C. & Trejo-Téllez, L.I. Biostimulant activity of phosphite in horticulture. *Sci Hortic-Amsterdam* **196**, 82-90 (2015).

32. King, M. *et al.* Defining the phosphite-regulated transcriptome of the plant pathogen *Phytophthora cinnamomi*. *Mol Genet Genomics* **284**, 425-435 (2010).
33. Smillie, R., Grant, B.R. & Guest, D. The mode of action of phosphite - Evidence for both direct and indirect modes of action on 3 *Phytophthora Spp* in plants. *Phytopathology* **79**, 921-926 (1989).
34. Adaskaveg, J.E., Förster, H., Hao, W. & Gray, M. in *Modern Fungicides and Antifungal Compounds*, Vol. 8 205-210 (University of California, Department of Plant Pathology and Microbiology; 2017).
35. Nimchuk, Z., Eulgem, T., Holt, B.E. & Dangl, J.L. Recognition and response in the plant immune system. *Annu Rev Genet* **37**, 579-609 (2003).
36. Dangl, J. Molecular specificity in the plant immune system. *Mol Biol Cell* **15**, 2a-2a (2004).
37. Baulcombe, D.C. VIGS, HIGS and FIGS: small RNA silencing in the interactions of viruses or filamentous organisms with their plant hosts. *Current Opinion in Plant Biology* **26**, 141-146 (2015).
38. Hou, Y. *et al.* A *Phytophthora* effector suppresses trans-kingdom RNAi to promote disease susceptibility. *Cell Host Microbe* **25**, 153-165 e155 (2019).
39. Dunstan, R.H., Smillie, R.H. & Grant, B.R. The effects of sub-toxic levels of phosphonates on the metabolism and potential virulence factors of *Phytophthora palmivora*. *Physiological and Molecular Plant Pathology* **3**, 205-220 (1990).
40. Barchietto, T., Saindrenan, P. & Bompeix, G. Characterization of phosphonate uptake in two *Phytophthora* spp. and its inhibition by phosphate. *Archives of Microbiology* **151**, 54-58 (1988).
41. Darakis, G.A., Bourbos, V.A. & Skoudridakis, M.T. Phosphonate transport in *Phytophthora capsici*. *Plant Pathology* **46**, 762-772 (1997).
42. Griffith, J., Coffey, I. & R., G.B. Phosphonate inhibition as a function of phosphate concentration in isolates of *Phytophthora palmivora*. *J Gen Microbiol*, 2109-2116 (1993).
43. Niere, J.O., Deangelis, G. & Grant, B.R. The effect of phosphonate on the acid-soluble phosphorus components in the genus *Phytophthora*. *Microbiol-Uk* **140**, 1661-1670 (1994).
44. Fenn, M. & Coffey, M. Studies on the in vitro and in vivo antifungal activity of fosetyl-Al and phosphorous acid. *Phytopathology* **74**, 606-611 (1984).
45. Martin, H., Grant, B.R. & Stehmann, C. Inhibition of inorganic pyrophosphatase by phosphonate—A site of action in *Phytophthora* spp.? *Pesticide Biochemistry and Physiology* **61**, 65-77 (1998).
46. Pastor, J.N., Buron-Moles, G., Rojo, F., Martin-Closas, L. & Almacellas, J. *In vitro* and *In vivo* antifungal activity of phosphite against *Phytophthora parasitica* in tomato. *Acta horticulturae*, 167-172 (2011).

47. Cai, M. *et al.* C239S Mutation in the beta-Tubulin of *Phytophthora sojae* confers resistance to zoxamide. *Frontiers in Microbiology* **7** (2016).
48. Cohen, Y., Rubin, A.E. & Galperin, M. Oxathiapiprolin-based fungicides provide enhanced control of tomato late blight induced by mefenoxam-insensitive *Phytophthora infestans*. *Plos One* **13** (2018).
49. Diriwächter, G., Sozzi, D., Ney, C. & Staub, T. Cross-resistance in *Phytophthora infestans* and *Plasmopara viticola* against different phenylamides and unrelated fungicides. *Crop Protection* **6**, 250-255 (1987).
50. Han, X. *et al.* Sensitivity of *Phytophthora capsici* to mandipropamid and its cross resistance with other fungicides. *Phytopathology* **38**, 173-177 (2011).
51. Liu, X., Cai, M., Miao, J. & Zhang, C. Molecular mechanism of resistance to CAA and OSBP fungicides in *Phytophthora capsici* and *P. sojae*. *Phytopathology* **108** (2018).
52. Pang, Z. *et al.* Resistance to the novel fungicide pyrimorph in *Phytophthora capsici*: risk assessment and detection of point mutations in CesA3 that confer resistance. *PLoS One* **8**, 1 -12, (2013).
53. Ziogas, B.N., Markoglou, A.N., Theodosiou, D.I., Anagnostou, A. & Boutopoulou, S. A high multi-drug resistance to chemically unrelated oomycete fungicides in *Phytophthora infestans*. *Eur J Plant Pathol* **115**, 283-292 (2006).
54. Hunter, S. in Faculty of Science, Vol. Masters of Science 152 (Univeristy of Waikato, 2018).
55. Hunter, S., Williams, N., McDougal, R., Scott, P. & Garbelotto, M. Evidence for rapid adaptive evolution of tolerance to chemical treatments in *Phytophthora* species and its practical implications. *PLoS One* **13** (2018).
56. Miao, J. *et al.* Resistance assessment for oxathiapiprolin in *Phytophthora capsici* and the detection of a point mutation (G769W) in PcORP1 that confers resistance. *Frontiers in Microbiology* **7**, 615 (2016).
57. Miao, J. *et al.* Activity of the novel fungicide oxathiapiprolin against plant-pathogenic oomycetes. *Pest Management Science* **72**, 1572-1577 (2016).
58. Miao, J., Chi, Y., Lin, D., Tyler, B.M. & Liu, X. Mutations in ORP1 conferring oxathiapiprolin resistance confirmed by genome editing using CRISPR/Cas9 in *Phytophthora capsici* and *P. sojae*. *Phytopathology* **108**, 1412-1419 (2018).
59. Miao, J., Lin, D., Peng, Q., Wang, Z. & Liu, X. N837 deletion in oxysterol binding protein-related protein confers oxathiapiprolin resistance in *Phytophthora capsici* and *P. sojae*. *Phytopathology* **108**, 24-24 (2018).
60. Alpey, L., Jimenez, J. & Glover, D. A *Drosophila* homologue of oxysterol binding protein (OSBP) - Implications for the role of OSBP. *Bba-Gene Struct Expr* **1395**, 159-164 (1998).

61. Beh, C.T., Cool, L., Phillips, J. & Rine, J. Overlapping functions of the yeast oxysterol-binding protein homologues. *Genetics* **157**, 1117-1140 (2001).
62. Lehto, M. & Olkkonen, V. The OSBP-related proteins: a novel protein family involved in vesicle transport, cellular lipid metabolism, and cell signalling. *Bba-Mol Cell Biol L* **1631**, 1-11 (2003).
63. Fairn, G.D. & McMaster, C.R. Emerging roles of the oxysterol-binding protein family in metabolism, transport, and signaling. *Cell Mol Life Sci* **65**, 228-236 (2008).
64. Raychaudhuri, S. & Prinz, W.A. The diverse functions of oxysterol-binding proteins. *Annu Rev Cell Dev Bi* **26**, 157-177 (2010).
65. Levine, T.P. & Munro, S. Dual targeting of Osh1p, a yeast homologue of oxysterol-binding protein, to both the golgi and the nucleus-vacuole junction. *Mol Biol Cell* **12**, 1633-1644 (2001).
66. Im, Y.J., Raychaudhuri, S., Prinz, W.A. & Hurley, J.H. Structural mechanism for sterol sensing and transport by OSBP-related proteins. *Nature* **437**, 154-158 (2005).
67. Taniguchi, M. *et al.* Mode of action of polygodial, an antifungal sesquiterpene dialdehyde. *Agr Biol Chem Tokyo* **52**, 1409-1414 (1988).
68. Brennan, N.J. *et al.* Fungicidal sesquiterpene dialdehyde cinnamates from *Pseudowintera axillaris*. *J Agr Food Chem* **54**, 468-473 (2006).
69. Best, E. Maori medical Lore. Notes on sickness and disease among the Maori people of New Zealand and their treatment of the sick; Together with some accounts of various beliefs, superstitions and rites pertaining to sickness and the treatment thereof as collected from the Tuhoe tribe. Part 1.- (Continued). *The Journal of the Polynesian Society* **14**, 1-23 (1905).
70. Calder, V.L., Cole, A.L.J. & Walker, J.R.L. Antibiotic compounds from New-Zealand plants 3. A survey of some New-Zealand plants for antibiotic substances. *J Roy Soc New Zeal* **16**, 169-181 (1986).
71. Bell, T.W. Medical notes on New Zealand. *New Zealand Medical Journal* **3**, 129-145 (1890).
72. Lunde, C.S. & Kubo, I. Effect of polygodial on the mitochondrial ATPase of *Saccharomyces cerevisiae*. *Antimicrob Agents Ch* **44**, 1943-1953 (2000).
73. Castelli, M.V., Lodeyro, A.F., Malheiros, A., Zacchino, S.A. & Roveri, O.A. Inhibition of the mitochondrial ATP synthesis by polygodial, a naturally occurring dialdehyde unsaturated sesquiterpene. *Biochemical pharmacology* **70**, 82-89 (2005).
74. Kubo, I. & Himejima, M. Anethole, a synergist of polygodial against filamentous microorganisms. *J Agr Food Chem* **39**, 2290-2292 (1991).

75. Kubo, I., Lee, S.H. & Ha, T.J. Effect of EDTA alone and in combination with polygodial on the growth of *Saccharomyces cerevisiae*. *J Agr Food Chem* **53**, 1818-1822 (2005).
76. Scher, J.M., Speakman, J., Zapp, J. & Becker, H. Bioactivity guided isolation of antifungal compounds from the liverwort *Bazzania trilobata* (L.) S.F. Gray. *Phytochemistry* **65**, 2583-2588 (2004).
77. Mongalo, N.I., Dikhoba, P.M., Soyingbe, S.O. & Makhafola, T.J. Antifungal, anti-oxidant activity and cytotoxicity of South African medicinal plants against mycotoxigenic fungi. *Heliyon* **4** (2018).
78. Rawson, A. *et al.* Stability of falcarinol type polyacetylenes during processing of *Apiaceae* vegetables. *Trends in food science & technology* **30**, 133-141 (2013).
79. Nam, N. *et al.* Furanocoumarins and Falcarindiol from *Angelica Dahurica*. *Journal of Science and Technology* **87** (2012).
80. Prior, R.M. *et al.* The polyacetylene falcarindiol with COX-1 activity isolated from *Aegopodium podagraria* L. *J Ethnopharmacol* **113**, 176-178 (2007).
81. Wang, C. *et al.* Identification of potential anticancer compounds from *Oplopanax horridus*. *Phytomedicine* **20**, 999-1006 (2013).
82. Miyazawa, M., Shimamura, H., Bhuva, R.C., Nakamura, S. & Kameoka, H. Antimutagenic activity of falcarindiol from *Peucedanum praeruptorum*. *J Agr Food Chem* **44**, 3444-3448 (1996).
83. Christensen, L.P. & Brandt, K. Bioactive polyacetylenes in food plants of the *apiaceae* family: occurrence, bioactivity and analysis. *J Pharmaceut Biomed* **41**, 683-693 (2006).
84. Blum, M. *et al.* Mandipropamid targets the cellulose synthase-like PiCesA3 to inhibit cell wall biosynthesis in the oomycete plant pathogen, *Phytophthora infestans*. *Molecular Plant Pathology* **11**, 227-243 (2010).
85. Gisi, U. & Sierotzki, H. Fungicide modes of action and resistance in downy mildews. *Eur J Plant Pathol* **122**, 157-167 (2008).
86. Studholme, D.J. *et al.* Genome sequences of six *Phytophthora* species associated with forests in New Zealand. *Genomics Data* **7**, 54-56 (2016).
87. Erwin, D.C.R., O. K; *Phytophthora diseases worldwide*. (American Phytopathological Society (APS press), Minnesota, USA; 1996).
88. Jeffers, S.N. & Martin, S.B. Comparison of two media selective for *Phytophthora* and *Pythium* species. *Plant Dis* **10**, 1038-1043 (1986).
89. Rueden, C.T.J., S.; Hiner M. C.; DeZonia B. E.; Walter, A. E.; Arena, E. T; Eliceiri, K. W.; ImageJ2: ImageJ for the next generation of scientific image data. *BMC Bioinformatics-BMC series* **18** (2017).

90. Andreassi, J., Gutteridge, S., Pember, S., Sweigard, J. & Rehberg, E. in World Intellectual Property Organisation. (ed. D. Pont) 1- 54 (US; 2013).
91. Waterhouse, A. *et al.* SWISS-MODEL: homology modelling of protein structures and complexes. *Nucleic Acids Res* **46**, W296-W303 (2018).
92. Lo, M. *et al.* Evaluation of fluorescence-based thermal shift assays for hit identification in drug discovery. *Anal Biochem* **332**, 153-159 (2004).
93. Horner, I.J. & Hough, E.G. Phosphorous acid for controlling *Phytophthora* taxon *Agathis* in kauri: glasshouse trials. *Plant Pathology*, 242-248 (2013).
94. Mulqueen, P. Recent advances in agrochemical formulation. *Advances in Colloid and Interface Science* **106**, 83-107 (2003).
95. Hunter, S., McDougal, R., Clearwater, M.J., Williams, N. & Scott, P. Development of a high throughput optical density assay to determine fungicide sensitivity of oomycetes. *J Microbiol Meth* **154**, 33-39 (2018).
96. Parra, G. & Ristaino, J.B. Resistance to mefenoxam and metalaxyl among field isolates of *Phytophthora capsici* causing *Phytophthora* blight of bell pepper. *Plant Dis* **85**, 1069-1075 (2001).
97. Geer, L.Y., Domrachev, M., Lipman, D.J. & Bryant, S.H. CDART: protein homology by domain architecture. *Genome Res* **12**, 1619-1623 (2002).
98. Ngo, M. & Ridgway, N.D. Oxysterol binding protein-related protein 9 (ORP9) Is a cholesterol transfer protein that regulates golgi structure and function. *Mol Biol Cell* **20**, 1388-1399 (2009).
99. Ridgway, N.D., Dawson, P.A., Ho, Y.K., Brown, M.S. & Goldstein, J.L. Translocation of oxysterol binding protein to Golgi apparatus triggered by ligand binding. *J Cell Biol* **116**, 307-319 (1992).
100. Horner, I.J., Hough, E.G. & B., H.M. Forest efficacy trials on phosphite for control of kauri dieback. *New Zealand Plant Protection* 7-12 (2015).
101. Horner, I.J., Hough, E.G. & Horner, M. in Trunk sprays and lower phosphite injection rates for kauri dieback control. (ed. I.J. Horner) 8 (Plant and Food Research, 2017).
102. Horner, I.J. in Trunk sprays and lower phosphite injection rates for kauri dieback control. (ed. I.J. Horner) 4 (Plant and Food Research, 2017).
103. Horner, I.J. in Trunk sprays and lower phosphite injection rates for kauri dieback control. (ed. I.J. Horner) 4 (Plant and Food Research, 2018).
104. O'Riordan, T. UN Sustainable development goals: How can sustainable/green chemistry contribute? The view from the agrochemical industry. *Current Opinion in Green and Sustainable Chemistry* **13**, 158-163 (2018).

105. Jin, H.R. *et al.* The antitumor natural compound falcarindiol promotes cancer cell death by inducing endoplasmic reticulum stress. *Cell Death Dis* **3** (2012).
106. Notabi, M.K., Olle, E., Walke, P., Andersen, M.O. & Arnspang, E.C. Lipid nanoparticles as drug delivery systems for cancer therapy: Uptake and response of falcarindiol and synthesis and effect of antibody conjugated nanoparticles. *Mol Biol Cell* **28** (2017).
107. Wang, J., Shao, L., Rao, T., Zhang, W. & Huang, W.H. Chemo-preventive potential of falcarindiol-enriched fraction from *Oplapanax elatus* on colorectal cancer Interfered by human gut microbiota. *Am J Chinese Med* **47**, 1381-1404 (2019).
108. Taniguchi, M. *et al.* Polygodial-induced sensitivity to rifampicin and actinomycin-D of *Saccharomyces cerevisiae*. *Agr Biol Chem Tokyo* **52**, 1881-1883 (1988).
109. Broccoli, V. & Caiazzo, M. NUCLEAR RECEPTORS: Oxysterols detour to neurodevelopment. *Nat Chem Biol* **9**, 70-71 (2013).
110. Kanaki, M., Tiniakou, I., Thymiakou, E. & Kardassis, D. Physical and functional interactions between nuclear receptor LXR alpha and the forkhead box transcription factor FOXA2 regulate the response of the human lipoprotein lipase gene to oxysterols in hepatic cells. *Bba-Gene Regul Mech* **1860**, 848-860 (2017).
111. Lala, D.S. *et al.* Activation of the orphan nuclear receptor steroidogenic factor 1 by oxysterols. *P Natl Acad Sci USA* **94**, 4895-4900 (1997).
112. Lee, M. & Fairn, G.D. Both the PH domain and N-terminal region of oxysterol-binding protein related protein 8S are required for localization to PM-ER contact sites. *Biochem Bioph Res Co* **496**, 1088-1094 (2018).
113. Lessmann, E. *et al.* Oxysterol-binding protein-related protein (ORP) 9 is a PDK-2 substrate and regulates Akt phosphorylation. *Cell Signal* **19**, 384-392 (2007).
114. Ma, L.Q. & Nelson, E.R. Oxysterols and nuclear receptors. *Mol Cell Endocrinol* **484**, 42-51 (2019).
115. Marceau, G. *et al.* Placental expression of the nuclear receptors for oxysterols LXR alpha and LXR beta during mouse and human development. *Anat Rec Part A* **283a**, 175-181 (2005).
116. Mouzat, K. *et al.* Absence of Nuclear Receptors for Oxysterols Liver X Receptor Induces Ovarian Hyperstimulation Syndrome in Mice. *Endocrinology* **150**, 3369-3375 (2009).
117. Volle, D.H. *et al.* Multiple roles of the nuclear receptors for oxysterols liver X receptor to maintain male fertility. *Mol Endocrinol* **21**, 1014-1027 (2007).
118. Wang, Y.J., Kumar, N., Crumbley, C., Griffin, P.R. & Burris, T.P. A second class of nuclear receptors for oxysterols: Regulation of ROR alpha and ROR gamma activity by 24S-hydroxycholesterol (cerebrosterol). *Bba-Mol Cell Biol L* **1801**, 917-923 (2010).

119. Xu, L.Y. *et al.* Nuclear Oxysterols, 25HC and 25HC3S, Regulate Nuclear Orphan Receptor Activities and Attenuate Intracellular Lipid Levels. *Faseb J* **23** (2009).
120. Yan, D. & Olkkonen, V.M. Characteristics of Oxysterol Binding Proteins, in *A Survey of Cell Biology* 253-285 (2008).